WO2011145737A1

WO2011145737A1 - Composition for improving condition of skin

Info

Publication number: WO2011145737A1
Application number: PCT/JP2011/061695
Authority: WO
Inventors: 秀二池上; 孝之利光; 義男大原; 英恵土橋; 伊藤　裕之
Original assignee: 株式会社明治
Priority date: 2010-05-21
Filing date: 2011-05-20
Publication date: 2011-11-24
Also published as: SG185410A1; JPWO2011145737A1; HK1178465A1; JP2016164144A; CN103025338B; JP5954828B2; CN103025338A

Abstract

The present invention demonstrates that the cultured product of propionic acid bacteria has a skin condition-improving effect. A composition containing the cultured product of propionic acid bacteria improves the condition of skin and, in particular, inhibits pigmentation. The composition is formed from components proven to be safe and to have superior gustatory characteristics on the basis of a long history of consumption, and long-term consumption of the composition is possible. Fermented milk components can be further added to the composition. When ingested, the composition can be expected to have an intestinal function-regulating effect and a skin condition-improving effect.

Description

Composition for improving skin condition

The present invention relates to a composition for improving skin condition comprising a culture of propionic acid bacteria. The present invention also relates to DHNA (1,4-dihydroxy-2-naphthoic acid; 1,4-dihydroxy-2-naphthoic acid), ACNQ (2-amino-3-carboxy-1,4-naphthoquinone; 2-amino -3-carboxy-1,4-naphthoquinone), or an analogue thereof, relates to a composition for improving skin condition.

Profec (Profec; manufactured by Meiji, trade name; "Profec" is a registered trademark of Meiji Co., Ltd.) is a fermented whey product of Propionibacterium freudenreichii ET-3 strain isolated from Emmental cheese, It has been developed as a material containing a component having an action of promoting the growth of bifidobacteria among internal bacteria (Non-patent Document 1). In subsequent studies, DHNA (1,4-dihydroxy-2-naphthoic acid) was identified as the main component involved in the growth promotion of bifidobacteria contained in Profec. When humans ingest Profec, it becomes clear that the bifidobacteria possessed in the intestines of individuals increases and the effect of intestinal regulation is demonstrated (Non-patent Document 2). ; "Mother's vitality" is a registered trademark of Meiji Co., Ltd.), "Mother's vitality milk" (Meiji, "Mother's vitality" is a registered trademark of Meiji Co., Ltd.), etc. have been commercialized and approved as food for specified health use. Yes. It has also been clarified that DHNA is administered to a colitis model animal to exhibit the effect of improving / preventing enteritis (Non-patent Document 3). On the other hand, the skin beautifying effect by ingesting yogurt has been studied mainly in human tests, and it has been confirmed that the intestinal regulation effect and the skin condition improving effect correlate well (Non-patent Document 4). Moreover, in the investigation test which compares a constipation person and a non-constipation person, possibility that the intestinal environment and a skin state are related is confirmed (nonpatent literature 5).

WO 2008/078387

An object of the present invention is to provide a composition for improving skin condition including a culture of propionic acid bacteria. And the subject of this invention is providing the composition containing the culture of propionic acid bacteria which has the improvement effect of skin condition especially.

Until now, the present inventors have repeatedly investigated the effect of skin beautification by ingesting yogurt, mainly in human tests. Among them, the present inventors confirmed that the intestinal regulating effect and the skin condition improving effect are well correlated. Furthermore, in the investigation study comparing constipation and non constipated person, to confirm the possibility of intestinal environment and skin condition is concerned.
Accordingly, the present inventors have intake Profec the intestinal action is authorized attempts whether consideration to improve skin condition. From the results, the present inventors found that the stratum corneum water content and texture score were significantly improved in the Profec intake group compared to the placebo group. In addition, it was confirmed that DHNA, which is an active ingredient of Profec, has an action of suppressing the production of melanin that causes stains. That is, the present invention relates to the following compositions and uses thereof.
[1] A composition for improving skin condition comprising at least one component selected from the group consisting of the following (a) to (c):
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
[2] The composition according to [1], wherein the propionic acid bacterium is Propionibacterium freudenreichii.
[3] The composition according to [1] or [2], which additionally contains a milk fermentation component.
[4] The composition according to [3], wherein the milk fermentation component is milk fermented with lactic acid bacteria belonging to the genus Lactobacillus and / or lactic acid bacteria belonging to the genus Streptococcus, or a mixture thereof.
[5] The composition according to any one of [1] to [4], wherein the culture of propionic acid bacteria is sterilized.
[6] Analogs of DHNA or ACNQ are 1,4-naphthoquinone, 2-methyl-1,4-naphthoquinone, 4-amino-2-methyl-1-naphthol, and 2-amino-3-chloro-1, The composition according to [1], which is selected from the group consisting of 4-naphthoquinone.
[7] The composition according to any one of [1] to [6], wherein the improvement in skin condition is selected from the group consisting of an improvement in texture density, an increase in stratum corneum water content, and a decrease in pigmentation.
[8] Food according to any one of [1] to [7], which is infant formula, infant formula, infant formula, etc., health functional food, sick food, dairy product or fermented milk Composition.
[9] Use of the composition according to any one of [1] to [8] for producing a skin condition improving composition.
[10] A pigmentation inhibitor in skin comprising at least one component selected from the group consisting of the following (a) to (c):
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
[11] The following (a) ~ method for improving skin conditions comprising the step of at least one component is orally administered to an animal selected from the group consisting of (c);
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
[12] The composition according to any one of [1] to [8], which is molded into a tablet.
[13] The pigment formation inhibitor according to [10], which is molded into a tablet.

The composition of the present invention has an action of improving the skin condition, particularly an action of inhibiting the production of melanin in the skin. Moreover, it has the effect | action which improves stratum corneum moisture content and texture score significantly.
The composition of the present invention can be produced by blending ingredients that have already been administered to humans as food or the like. Therefore, the composition of the present invention is already guaranteed a high level of safety and can be taken continuously. That is, with the composition of the present invention, continuous improvement of the skin condition can be expected.
In a preferred embodiment, the composition of the present invention is provided by a combination of components that are already widely consumed as general foods, liquid foods, and the like. Therefore, by continuously ingesting the composition of the present invention as a food such as yogurt, a state in which the production of melanin in the skin is inhibited can be continued.

It is a graph which shows the time-dependent comparison in the group of a stratum corneum moisture amount before and after ingestion of a test meal. The vertical axis represents the amount of keratin water (arbitrary unit; AU). The horizontal axis represents the test meal A (placebo) intake group, test meal B (Profec-containing acidic drink) intake group, and test meal C (Profecfe-containing yogurt drink) intake group, respectively. The vertical axis represents the amount of horny water calculated from the capacitance measured with a corneometer, and the horizontal axis represents the intake period (weeks) of the test meals A to C. In the figure, * indicates a significant difference in risk rate p <0.05. It is a graph which shows the time-dependent comparison within the group of a texture score before and after ingestion of a test meal. The vertical axis shows the texture score. The horizontal axis represents the test meal A (placebo) intake group, the test meal B (Profec-containing acidic drink) intake group, and the test meal C (Profec-containing yogurt drink) intake group, respectively. The vertical axis represents the texture score measured with “Robo Skin Analyzer” (trade name), and the horizontal axis represents the intake period (weeks) of the test meals A to C. In the figure, * indicates a significant difference in risk rate p <0.05. It is a graph which shows the time-dependent comparison in the group of the number of defecations before and after ingestion of a test meal. The vertical axis shows the average number of defecations per week. The horizontal axis represents the test meal A (placebo) intake group, the test meal B (Profec-containing acidic drink) intake group, and the test meal C (Profec-containing yogurt drink) intake group, respectively. In the figure, * indicates a significant difference in risk rate p <0.05. It is a graph which shows IL-1ra / IL-1 (alpha) ratio in a stratum corneum. There was no difference in the IL-1ra / IL-1α ratio before and after the intake regardless of the test meal. In the figure, the vertical axis represents the IL-1ra / IL-1α ratio of each group. It is a graph which shows IL-8 in a stratum corneum. In the figure, the vertical axis represents the content (pg) of IL-8 per 1 μg of protein in the stratum corneum. IL-8 in the stratum corneum was significantly increased before and after intake in the test meal A (placebo) intake group. In groups other than the test food A (placebo) intake group, there was no change in the IL-8 concentration before and after the intake. It is a graph which shows the melanin production inhibitory effect of DHNA and ACNQ. In the figure, the vertical axis represents the amount of melanin produced in the cell culture (absorbance at 405 nm), and the horizontal axis represents each test compound. Both DHNA and ACNQ were suggested to have a strong melanin production inhibitory effect.

The present invention provides a composition for improving skin condition, or a pigmentation inhibitor in skin, comprising at least one component selected from the group consisting of (a) to (c) below.
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof The composition for improving skin condition of the present invention, or a pigmentation inhibitor in skin, is a culture of propionic acid bacteria. Including things. Propionic acid bacteria are gram-positive anaerobic bacteria belonging to the genus Propionibacterium, and are microorganisms that produce propionic acid oxygen-freely from sugars. Specifically, the following microorganism cultures can be added to the composition of the present invention. That is, Propionibacterium freudenreichii, Propionibacterium toeni (P. thoenii), Propionibacterium acidipropionici (P. acidipropionici), Propionibacterium genseny (P. jensenii) and the like. These propionic acid bacteria are microorganisms used for cheese production. In addition, the following microorganisms can also be shown as propionic acid bacteria. Ie, Propionibacterium avidum (P. avidum), Propionibacterium acnes (P. acnes), Propionibacterium lymphophilum (P. lymphophilum), Propionibacterium granulosam (P. granulosam) is there.

A method for isolating these microorganisms from nature and fermented milk is known. Propionic acid bacteria can also utilize microorganisms that are used in Swiss cheese production and the like. The culture of propionic acid bacteria in the present invention refers to those obtained by culturing the above propionic acid bacteria under appropriate culture conditions. Methods for culturing propionic acid bacteria are known. In the culture of propionic acid bacteria, the conditions described in WO03 / 016544A1 and the like can be applied. For example, as a medium for culturing propionic acid bacteria, a composition in which beer yeast extract or the like is added to skim milk powder or a proteolytic processed product of skim milk powder is known. A culture of propionic acid bacteria can be obtained by inoculating a suitable medium with Propionibacterium re freudenreichii and culturing under conditions that allow propionic acid bacteria to grow.

As a method of culturing propionic acid bacteria at a high concentration, whey protein concentrate (Whey Protein Concentrate:, hereinafter also referred to as WPC) or its enzyme degradation product as a processed product of whey, minerals and monosaccharides There is a method of culturing propionic acid bacteria using an added medium (Japanese Patent Publication No. 10-304871). For example, a culture obtained by culturing Propionibacterium oni freudenreichii in a medium containing WPC is preferable as the culture of propionic acid bacteria in the present invention. Alternatively, as an efficient method for culturing propionic acid bacteria, there is a method in which bifidobacteria and propionic acid bacteria are cultured while circulating the culture solution in different culture tanks (Japanese Patent Publication No. 8-66178). A culture of propionic acid bacteria obtained by these culturing methods can also be added to the composition of the present invention.

As described above, by using a processed product of whey as a whey protein source as a main component of the medium, propionic acid bacteria can be cultured at high density. In addition to processed whey products, a mixture of minerals and monosaccharides can be used as a medium component. Here, the following components can be exemplified as processed products of whey. That is, it is a whey powder, a protease-treated product of whey or whey powder. At this time, in order to reduce the sugar concentration in the medium, WPC and / or whey protein isolate (Whey Protein Isolate: hereinafter referred to as WPI) may be used as a processed product of whey. These components can be added to the medium, and an appropriate amount of sugar and deficient minerals can be added thereto to adjust the composition of the medium for culturing propionic acid bacteria.

Here, whey (whey) is a water-soluble component remaining when, for example, fat, casein, fat-soluble vitamins and the like are removed from milk. Whey generally produces acid casein and quark from cheese whey, rennet whey (or sweet whey) and skim milk that are obtained as by-products when natural cheese and rennet casein are produced. Casein whey and quark whey (or acid (acid) whey) are obtained as by-products. The main components of whey include protein (β-lactoglobulin, α-lactalbumin, etc.), lactose, water-soluble vitamins, and salts (minerals). It is clarified from research as an ingredient.

Processed products of whey, including those mentioned above, whey concentrated whey, whey powder dried whey (whey powder), and major proteins in whey are subjected to ultrafiltration (UF) method Degreased whey protein concentrate (WPC) that has been concentrated and then dried by removing the fat from the whey by microfiltration (MF), centrifugation, etc., concentrated by the UF method, and then dried WPC (low fat / high protein), whey protein isolate (WPI), nanofiltration (Nanofiltration: NF), desalted by electrodialysis, etc., dried desalted whey, minerals derived from whey-derived mineral components, and concentrated by centrifugation etc. For example, concentrated whey. Of these, WPC containing 15% to 80% dry protein (solid content) as dry weight is a protein-concentrated whey powder on 30 March 1998 due to a partial amendment to the Ordinance of the Ministry of Milk, etc. Defined in the product (concentrated whey, whey powder, WPC, whey protein concentrated powder, regardless of the presence or absence of a desalting step, as long as they have undergone the manufacturing process specified by the Ministerial Ordinance)

As described above, WPC is obtained by concentrating main whey proteins and the like by ultrafiltration and then drying. In general, it is a generic name for whey proteins in which about 25% or more of the solid content is whey protein. It can be obtained by reducing lactose, salts, etc. from whey, relatively strengthening whey protein, and adjusting the solid content to about 25% to about 80%. At this time, the WPC in particular containing 15 to 80% milk protein as dry weight, the milk or the like ordinance, it is defined as a protein concentrate whey powder.
The standard method for producing whey protein concentrate (WPC) is as follows.
(1) A step of concentrating whey after membrane separation. Or (2) A step of concentrating and drying the whey after membrane separation.
In addition, a general apparatus and method can be used for the concentration treatment, for example, a vacuum evaporator (evaporator), a vacuum kettle, a thin film vertical ascending tubular concentrator, a thin film vertical descending tubular concentrator, a plate type concentrator. A method of heating under reduced pressure using a machine or the like can be used. Also, a general apparatus or method can be used for the drying process, for example, spray drying (spray dryer) method, drum drying method, freeze vacuum drying (freeze dryer) method, vacuum (reduced pressure) drying method, etc. Can be used.

As described above, WPI is obtained by concentrating main whey proteins and the like by an ion exchange resin method, an electrodialysis method, and the like, and then drying them. Generally, it is a generic term for those in which about 85% to about 95% of the solid content is whey protein. It can be obtained by reducing lactose, salts, etc. from whey, relatively strengthening whey protein, and adjusting it to about 90% (85% to 95%) of the solid content.
A standard method for producing whey protein isolate (WPI) is as follows.
(1) A step of concentrating whey after membrane separation, ion exchange resin treatment or electrodialysis treatment. Or (2) A step of concentrating and drying the whey after membrane separation, ion exchange resin treatment or electrodialysis treatment.
In addition, a general apparatus and method can be used for the concentration treatment, for example, a vacuum evaporator (evaporator), a vacuum kettle, a thin film vertical ascending tubular concentrator, a thin film vertical descending tubular concentrator, a plate type concentrator. A method of heating under reduced pressure using a machine or the like can be used. Also, a general apparatus or method can be used for the drying process, for example, spray drying (spray dryer) method, drum drying method, freeze vacuum drying (freeze dryer) method, vacuum (reduced pressure) drying method, etc. Can be used.

In the present invention, the following composition can be exemplified as a medium suitable for cultivation of propionic acid bacteria. That is, the protein content is 1% to 5%, preferably 1.5% to 4%. The carbohydrate content is 1% to 4%, preferably 1.5% to 3%. In order to obtain such a content, the addition amount (blending amount) of whey, a processed product of whey or the like, or a processed protease product thereof is adjusted. Further, the sugar is preferably not a lactose but a monosaccharide obtained by treating glucose or lactose with lactase. In addition, all the numerical values shown in this specification are weight ratios (W / W%). When the composition is expressed in% (percentage), it is the weight ratio (W / W%) unless otherwise specified.

In order to reduce the cost of the medium and obtain a culture suitable for edible or oral administration, a lactase treatment solution of whey mineral can be used as a source of carbohydrates and minerals. Specifically, WPC or WPI can be used as a protein source, and whey minerals can be used as a saccharide source and a mineral source. When a mixture of the two optimization rates is used as a raw material for the medium, propionic acid bacteria can be cultured at a higher concentration than when whey powder is used as the raw material for the medium. A detailed method for preparing a medium for culturing propionic acid bacteria is shown below. That is, after reducing WPC or WPI (bovine), the protein is degraded with a protease. Protease is an endo-exo type derived from Aspergillus oryzae, and the amount of protease used is 3% of the protein to be degraded. The protease reaction proceeds at a temperature of 50 ° C. and a pH of 7, and is continuously stirred for 3 to 5 hours until the pH does not drop. For whey minerals, lactase is used to break down lactose. The amount of lactase used should be 2% to 8% of the carbohydrates that are degraded. The lactase reaction proceeds at a temperature of 50 ° C. to 60 ° C. (preferably 55 ° C.), a pH of 5 to 6, and is continuously stirred until lactose is completely decomposed.

As described above, the final medium composition is a protein concentration of 1% to 5% (preferably 1.5% to 4%), and a carbohydrate concentration of 1% to 4% (preferably 1.5% to 3%). %)), These two WPC or WPI protease-treated products and whey mineral lactase-treated products are mixed. Finally, after adding ingredients commonly used for the culture of propionic acid bacteria such as yeast extract, sodium sulfate and asparagine as the composition of the medium, the pH is adjusted to 5-8 (preferably 5.5-7.5), The medium preparation is finished.

The culture process of propionic acid bacteria is as follows. Specifically, the temperature of the medium is adjusted to 20 ° C. to 40 ° C., and the starter is inoculated so that the viable cell count immediately after the start of culture is 10 ⁷ to 10 ⁸ cfu / ml, and cultured for 3 to 4 days. . The pH is maintained at 5.5 to 7.5 with an aqueous potassium carbonate solution. Glucose can be additionally added during the culture. The concentration of propionic acid bacteria contained in the thus obtained culture reaches about 5 times the conventional concentration.

The above culture conditions are particularly suitable for culturing propionic acid bacteria for cheese. In addition to Propionibacterium freudenreichii, Propionibacterium acidipropionici, Propionibacterium jensenii, Propionibacterium thoenii and the like can be used as propionic acid bacteria for cheese. More specifically, a culture from which the following strains can be obtained as propionic acid bacteria can be used in the present invention. That is, Propionibacterium freudenreichii ATCC 6207, P. freudenreichii ATCC 8262, P. freudenreichii IFO 12424, P. freudenreichii IFO 12426, P. freudenreichii IFO 12391, P. freudenreichii ET-8 (FER-8) These propionic acid bacteria can be cultivated alone, or a plurality of strains can be mixed and cultured. Alternatively, after culturing a plurality of microorganisms alone, the obtained cultures can be mixed. The culture thus obtained can be directly used for eating and drinking. Alternatively, it can be pulverized or liquefied, and processed into a form that is easy to handle as a functional raw material. That is, the culture obtained by culturing the propionic acid bacterium can be blended with the composition of the present invention directly or after being processed.

Further, those skilled in the art can appropriately adjust the composition of the medium and the culture conditions in order to optimize these known methods. For example, in the medium composition, in addition to casein, WPC, WPI, etc. as a nitrogen source, various amino acids and their salts are additionally added to optimize and enhance the propionic acid bacteria growth ability and skin condition improvement effect. be able to. Further, not only the composition of the medium but also the culture conditions can be adjusted to increase the concentration, temperature, pressure, etc. of the oxygen in the culture atmosphere to optimize and enhance the propionic acid bacteria proliferative ability and skin condition improving effect.

In the culture of propionic acid bacteria of the present invention, as long as the effect of improving the skin condition is maintained, its fraction components can also be used. Accordingly, the culture of propionic acid bacteria includes, for example, the culture itself of propionic acid bacteria, the culture supernatant, the cells themselves, their extracts, their dried products, or their dilutions. Here, for example, the action of promoting the improvement of the skin condition of the fraction component of the culture of propionic acid bacteria is, for example, 30% or more compared to the culture of propionic acid bacteria of the same origin (before fractionation), When it is preferably 50% or more, more preferably 70% or more, it can be said that the effect of improving the skin condition of the propionic acid bacteria culture itself was maintained.

The culture of the propionic acid bacterium of the present invention can be sterilized after the cultivation is completed and can be blended in the composition of the present invention. Alternatively, the composition (mixture) can be sterilized after blending with milk fermentation components and the like. For example, in the case of milk, a sterilization method or the like is defined in an ordinance such as milk, and the following heat sterilization treatment is generally performed. That is, low temperature long time sterilization, high temperature short time sterilization, ultra high temperature (instant) sterilization.

The sterilization method or heat sterilization treatment equivalent to that of milk can be applied to the culture of propionic acid bacteria of the present invention or a composition containing the same. These heat sterilization treatments can be performed batchwise (in batch units) or continuously. At this time, the treatment temperature and treatment time vary depending on the respective heat sterilization treatment, but preferably 60 ° C. to 150 ° C., in the range of 0.1 second to 1 hour, more preferably 70 ° C. to 150 ° C., 0.5 second to 45 minutes. The range is more preferably 80 ° C. to 150 ° C., and the range of 1 second to 30 minutes is selected according to the sterilization method described above. In sterilizing the culture of propionic acid bacteria, it is desirable to keep the amount of dissolved oxygen in the treatment liquid reduced. Therefore, in the heat sterilization treatment, it is preferable that the inert gas atmosphere is continuously maintained as necessary. Examples of the inert gas include nitrogen gas, argon gas, carbon dioxide gas, etc. Especially, nitrogen gas is present in a large amount in the air, the cost is relatively low, and safety has been confirmed. It is desirable as an inert gas because it does not affect the flavor and quality of food and drink. Alternatively, in the heat sterilization treatment, it is preferable to maintain an atmosphere in a vacuum (reduced pressure) state as necessary. Examples of the vacuum state include a vacuum degassing process.

The present inventors have confirmed that the skin condition improving effect is maintained in the sterilized product of the propionic acid bacteria culture. That is, in the present invention, the effect of improving the skin condition of the culture of propionic acid bacteria is maintained even after the culture is sterilized. Normally, the effect of lactic acid bacteria on the host depends on the action of live bacteria. Therefore, it was an unexpected finding that a beneficial effect (a useful function) was found not only before and after sterilization of the culture of propionic acid bacteria. Probiotics and prebiotics have been reported to improve the intestinal environment and stimulate immunity. In general, probiotics refer to microorganisms that have a beneficial effect on the host when introduced into the intestine of the host in a living state. In contrast to probiotics, prebiotics refer to substances that have a beneficial effect on the host by acting on microorganisms that originally lived in the intestines. For example, several types of lactic acid bacteria have been reported as probiotics having skin beautifying effects, particularly in human tests. However, since these lactic acid bacteria are probiotics that act as live bacteria, their production and quality control have not been easy. Furthermore, in general, a microbial preparation has a limit in storage stability. For example, after a microbial preparation is produced, it is often unbearable for a long time even if it is stored at a low temperature.

In contrast to probiotics such as live bacteria of lactic acid bacteria, the culture of propionic acid bacteria of the present invention also functions as prebiotics. At this time, in the sterilized product (prebiotic) of the culture of the propionic acid bacterium of the present invention, the activity of the microorganism (propionic acid bacterium) is stopped, and the quality does not change. Therefore, the prebiotics such as the culture of propionic acid bacteria of the present invention can stably maintain the skin condition improving effect. That is, since the culture of propionic acid bacteria of the present invention or a composition containing the same is a prebiotic that also acts as a dead bacteria, its production and quality control are easy. Furthermore, the preparations and the like based on the present invention can be stored at room temperature for a long period of time. In general, when the effect of lactic acid bacteria is expected by oral administration, it often depends on the action of live bacteria, and the influence of gastric acid must be considered. This is because the number of viable bacteria of lactic acid bacteria decreases due to the influence of gastric acid, and a sufficient amount of live bacteria cannot be delivered into the intestine. On the other hand, in this invention, the improvement effect of the skin state by the culture of propionic acid bacteria does not depend on the effect | action by the living bacteria. Therefore, in the present invention, even by oral administration, a sufficient skin condition improving effect can be achieved without considering the influence of gastric acid.

In addition, it is known that in the case of lactic acid bacteria or lactic acid bacteria cultures, generally, the intestinal regulation effect by improving the intestinal flora and the skin beautifying effect always correlate. That is, in the case of lactic acid bacteria, the effect of improving the skin condition is exhibited depending on the effect of regulating the intestines. Similarly, in the case of propionic acid bacteria, it has been clarified that the effect of improving the skin condition is exhibited depending on the intestinal regulating effect. However, in the case of the culture of propionic acid bacteria of the present invention, it has also been clarified that the skin beautifying effect is exhibited independently of the intestinal regulating effect. That is, the composition or the pigment formation inhibitor of the present invention is expected to have a skin beautifying effect independent of the intestinal regulating effect in addition to the skin beautifying effect based on the intestinal regulating effect by using a culture of propionic acid bacteria. can do.

The culture or sterilized product of the propionic acid bacterium of the present invention can be processed into powder or liquid. For example, an appropriate excipient may be added to the culture or sterilized product of the present invention to adjust the solid content concentration to 30% to 40%, and then dried to be powdered. Here, known excipients can be used, such as skim milk powder, whey powder, raw starch, dextrin, etc., as well as WPC, WPI, modified starch, etc. as necessary. Can be used. A known method can also be used for drying. For example, a method of spray-drying the culture or sterilized product of the present invention as it is, or the culture or sterilized product of the present invention can be used. Alternatively, a method of spray drying after mixing the reducing solution of the excipient and concentrating until the solid content concentration becomes 30% to 40% can also be used. The dried product (powder, etc.) of the culture or sterilized product of the present invention can be stably treated for a long period of time by deoxidation treatment (such as nitrogen encapsulation or addition of oxygen scavenger) when filling the packaging material or container. Can be saved. In addition, it can be processed into a triturated preparation (0.2% powdered powder) for easy use in foods. As the modified starch, specifically, soluble starch, British gum, oxidized starch, starch ester, starch ether and the like can be used in addition to dextrin.

It is known that a culture of propionic acid bacteria generally has an effect of promoting the growth of lactic acid bacteria. A culture of a propionic acid bacterium having such an action or a processed product thereof is called “Bifidogenic Growth Stimulator” (BGS). As long as this BGS has an effect of improving the skin condition, it can be used as a culture of the propionic acid bacterium of the present invention.

As the culture of the propionic acid bacterium of the present invention, a whey fermented product by the propionic acid bacterium is preferable. For example, a propionic acid bacterium culture obtained by fermenting Propionibacterium oni freudenreichii -3 ET-3 strain producing BGS with whey powder reducing solution (10%) can be contained as an active ingredient in the composition of the present invention. . Here, the culture of propionic acid bacteria containing BGS is called “Profec”, and it is approved as a component involved in food for specified health use. As a composition containing this “Profec”, B.G.S.powder (made by Meiji, trade name), tummy vitality tablet (made by Meiji, trade name; “Takaka vitality” is a registered trademark of Meiji Co., Ltd.) are commercially available. Therefore, “B.G.S.powder” or “tummy vitality tablet” can also be used as the composition of the present invention. It is known that an excellent intestinal effect can be expected from fermented whey of propionic acid bacteria. However, it has not been known that the culture of propionic acid bacteria shows an effect of improving the skin condition.

In particular, BGS contained in Profec includes 1,4-dihydroxy-2-naphthoic acid; 1,4-dihydroxy-2-naphthoic acid (DHNA) and 2-amino-3-carboxy-1,4-naphthoquinone ; 2-amino-3-carboxy-1,4-naphthoquinone (ACNQ). Among them, DHNA is a biosynthetic intermediate of vitamin K2 (menaquinone) in microorganisms. These DHNA and ACNQ promote the growth of bifidobacteria by efficiently reoxidizing NADH produced during the energy metabolism process of bifidobacteria. Therefore, either or both of the following components (i) and (ii) can be used as a culture of propionic acid bacteria. That is, the present invention
(I) 1,4-dihydroxy-2-naphthoic acid (DHNA) or an analogue thereof, and (ii) 2-amino-3-carboxy-1,4-naphthoquinone (ACNQ) or an analogue thereof, or Provided is a composition for improving skin condition comprising both.

DHNA and ACNQ production methods have already been established, and those skilled in the art can easily synthesize and obtain them based on known literatures. For example, DHNA can be synthesized according to the method described in JP-A-2007-284449, but is not limited thereto. ACNQ can be synthesized according to the methods described in JP-A-7-289273, JP-A-3265193, JP-A-2003-89683, JP-A-4072430, JP-A-35332226 and the like, but is not limited thereto.

In addition, the present invention relates to a composition for improving skin condition, comprising either an analog of DHNA, an analog of ACNQ, or both. Examples of analogs of DHNA and ACNQ include, but are not limited to, the following compounds: That is, 1, 4-naphthoquinone, 2-methyl-1, 4-naphthoquinone, 4-amino-2-methyl-1-naphthol, 2-amino-3-chloro-1, 4-naphthoquinone. These analogs are also known to be produced in cultures of microorganisms used in the production of fermented milk (Japanese Patent Laid-Open No. 7-289273). Therefore, these analogs can be used as they are in the composition of the present invention by blending the culture or the fraction components thereof. Alternatively, these analogs can be purified together with DHNA or ACNQ and used in the composition of the present invention.

In the present invention, the dose of the composition for improving skin condition containing the above components (i) and / or (ii) is usually determined for adults using the amount of DHNA contained in the culture of propionic acid bacteria as an index. On the other hand, the amount of DHNA contained in the culture of propionic acid bacteria is generally in the range of 0.01 μg / kg to 100 mg / kg. However, lower doses may be sufficient, and conversely higher doses may be required. Then, it can be divided into 2 to 4 times a day for administration. The specific dose can be set in consideration of the patient's condition such as age and weight, the administration route, the degree of improvement effect actually expected, and the like. At this time, the preferred administration route in the present invention is oral administration.

Profec is specifically approved as an ingredient in foods for specified health use because it specifically increases Bifidobacterium in the human intestine (Nobuo Yoda: ILSI, No. 80, 5-13) (2004)). Currently, "BGSpowder" and "Tummy Vitality Tablet" are commercially available as compositions containing Profec. Therefore, it can be said that there is no difficulty in obtaining the composition of the present invention. However, it has not been known that feeding animals with Profec inhibits pigment formation in the skin. That is, the present invention
(I) 1,4-dihydroxy-2-naphthoic acid (DHNA) or an analog thereof, and (ii) 2-amino-3-carboxy-1,4-naphthoquinone (ACNQ) or an analog thereof, or A pigmentation inhibitor in the skin comprising both is provided. Alternatively, the present invention, any of the components (i) and (ii), or includes both relates to a pharmaceutical composition for inhibiting the formation of the dye in the animal skin. At this time, the preferred animal in the present invention is a human.

When 1,4-dihydroxy-2-naphthoic acid (DHNA) is added to the composition of the present invention, it is desirable that the dissolved oxygen content of the composition be kept in a reduced state. This is because DHNA is decomposed by dissolved oxygen, and the concentration of DHNA decreases during storage. A method for reducing the amount of dissolved oxygen in a composition containing DHNA is known (WO2004 / 85364). Specifically, when the composition of the present invention is in a liquid state, dissolved oxygen can be replaced with a gas other than oxygen by bubbling the liquid composition with a gas not containing oxygen. At this time, nitrogen gas is preferable as the gas not containing oxygen. Further, dissolved oxygen can be removed by subjecting the liquid composition to a vacuum degassing treatment or the like. On the other hand, the amount of dissolved oxygen can be kept low by blending a compound having antioxidant ability together with DHNA. A known antioxidant can be used for the compound having antioxidant ability. Specific examples include hyposulfite, ascorbic acid (vitamin C), erythorbic acid, carotene, tocopherol, and polyphenols having an antioxidant action.

In addition to synthetic products, polyphenols derived from natural products can also be used as polyphenols. For example, polyphenols derived from teas, grapes, lemons, coffee, Murasakimochi, soybeans and the like are known. Juices such as fruits, vegetables, seeds, plant leaves, etc., containing these polyphenols, or extracts thereof can be blended as polyphenols in the composition of the present invention. For example, a polyphenol extract can be obtained by extraction with water or an organic solvent. Concentrates, purified products, and dried products of products containing these natural polyphenols can also be blended in the composition of the present invention as polyphenols.

The amount of dissolved oxygen can be reduced by setting the additive amount of the antioxidant to be equal to or more than the additive amount normally used for antioxidant purposes, depending on the type of antioxidant. For example, when ascorbic acid is added alone to the composition of the present invention without bubbling with an inert gas and the stability of DHNA is expected reliably, 1g or more will be added. On the other hand, the amount of antioxidant generally added can be set, for example, to 1 μg to 2 g, preferably 150 μg to 1.5 g, more preferably about 1 mg to 1 g. At this time, the antioxidant can be added before, after or simultaneously with the addition of DHNA to the composition of the present invention.

The culture of the propionic acid bacterium of the present invention is blended in a ratio of, for example, 0.001% to 20%, preferably 0.01% to 15%, more preferably 0.05% to 10% with respect to the entire composition of the present invention. be able to. The composition of the present invention can be made into an arbitrary dosage form such as powder, solid, etc. by liquid, paste, or drying. The composition of the present invention can be prepared by blending propionic acid bacteria cultures with ingredients suitable for oral administration, pharmaceutically acceptable carriers, and the like. More specifically, it can be formulated into tablets, capsules, granules, powders, syrups and the like. Or it can also supply in the state which disperse | distributed the culture of propionic acid bacteria to the milk fermentation component. These various preparations are mainly used in the pharmaceutical formulation technology field such as excipients, binders, disintegrants, lubricants, flavoring agents, solubilizers, suspending agents, coating agents, solvents, and isotonic agents. It can be formulated according to conventional methods while applying known adjuvants that can be used normally. Moreover, minerals, such as calcium, can be mix | blended with a suitable quantity. Furthermore, vitamins, minerals, organic acids (including fatty acids such as short chain fatty acids), saccharides, amino acids, peptides, and the like can be blended in appropriate amounts.

In the composition of the present invention, a milk fermentation component can be additionally blended. In the present invention, the milk fermentation component refers to a processed milk product obtained by fermenting animal milk by the action of microorganisms or enzymes. In the present invention, animal milk refers to milk, buffalo milk, goat milk, sheep milk, horse milk, and the like. In particular, milk (cow milk) is economically advantageous because it can be easily obtained in large quantities. The milk fermentation component of the present invention can be prepared not only from the milk itself collected from the animal's living body, but also from its fractionated components and processed products. Here, as a milk fraction component or processed product, skim milk, partially skim milk, reduced full fat milk, reduced skim milk, reduced partial skim milk, full fat concentrated milk, skim concentrated milk, partial skim concentrated milk, full fat powder Examples include milk, skim milk powder, partially skim milk powder, casein, whey, reduced whey, concentrated whey, whey powder, WPC, WPI, cream, butter, buttermilk, buttermilk powder and the like. These fractionated components or processed products derived from milk are sometimes called raw milk. The raw milk can be used as a raw material for the milk fermentation component alone or mixed with different raw milk.

In the present invention, the milk fermentation component can be obtained as a culture fermented by adding microorganisms to milk. As long as the culture of this microorganism is combined with propionic acid bacteria and exhibits an effect of improving the skin condition, the fraction component can be used as the milk fermentation component of the present invention. Microorganisms used for the purpose of milk fermentation are generally called starters, and lactic acid bacteria or bifidobacteria are preferred as the microorganisms. Specifically, milk fermentation components can be obtained using lactic acid bacteria or bifidobacteria belonging to the following genera as a starter. That is, the genus Lactobacillus, Streptococcus, Enterococcus, Lactococcus, Leuconostoc, Pediococcus, Bifidobacterium and the like. More specifically, it is preferable to obtain a milk fermentation component by the following microorganisms. That is, the lactic acid bacteria, Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Enterococcus faecium, Enterococcus faecalis, Lactobacillus acidophilus, Lactobacillus brevis, Lactobacillus casei, Lactobacillus helveticus, Lactobacillus delbrueckii subsp. Bulgaricus, Lactobacillus delbrueckii subsp. Lactis, Lactobacillus gasseri, Lactobacillus mucosae, Lactobacillus murinus, Lactobacillus plantarum, Lactobacillus oris, Lactobacillus reuteri, Lactobacillus rhamnosus, etc., and Bifidobacterium include Bifidobacterium longum, Bifidobacterium bifidum, Bifidobacterium breve and the like.

Here, the Bulgarian bacterium (Lactobacillus delbrueckii subspecies bulgaricus) of the present invention is used in a starter in combination with Thermophilus OLS3059 (Streptococcus thermophilus OLS3059), and has the ability to form a card of fermented milk (milk fermentation component) Examples include, but are not limited to, lactic acid bacteria obtained by separating (isolating) from plain yogurt, hard yogurt, and soft yogurt manufactured by Meiji Co., Ltd.

Thermophilus OLS3059 (Streptococcus ophilthermophilus OLS3059) is registered with the independent administrative corporation National Institute of Advanced Industrial Science and Technology Patent Organism Depository Center: Ferm BP-10740 (Indication for identification: Streptococcus thermophilus OLS3059, Deposit date (date of deposit): Heisei November 29, 18).

In addition, Bulgaria bacteria, for example, in the administrative agency National Institute of Advanced Industrial Science and Technology Patent Biological Deposit Center: FERM BP-10741 (Indication for identification: Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1, deposit date (date of deposit): November 29, 2006), which is the Bulgarian fungus OLL1073R-1 (Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1).

A method for separating these microorganisms from the natural world and fermented milk is known. Alternatively, microorganisms that have already been separated (isolated) can be obtained by distribution of cell banks or the like. On the other hand, some starters for obtaining milk fermentation components are commercially available. And the milk | loop fermentation component prepared with these commercially available starters can also be utilized by mix | blending with the composition of this invention. In addition, several products are marketed by the difference in pH, physical property, etc. of fermented milk (milk fermentation component) actually prepared. Here, the physical properties of fermented milk refer to tension, smoothness, and the like. A commercially available starter should be used as a starter for obtaining the fermented milk component of the present invention as long as it improves the skin condition when administered with a culture of propionic acid bacteria, and particularly inhibits pigment formation in the skin. Can do.

In order to obtain the milk fermentation component of the present invention, raw milk can be inoculated using the following microorganism as a starter. That is, Lactobacillus bulgaricus (L. bulgaricus), Streptococcus thermophilus (S. thermophilus), Lactobacillus lactis (L. lactis) and the like. In general, in the preparation of fermented milk, raw material milk may be added with one or more selected from lactic acid bacteria and yeast other than these lactic acid bacteria. However, in any case, in the present invention, it is possible to use a mixed starter of Lactobacillus bulgaricus (L. bulgaricus) and Streptococcus thermophilus (S. thermophilus) standardized as a yogurt starter in the Codex standard. preferable. In addition, when the microorganisms are additionally used, the microorganisms can be additionally mixed in these mixed starters in consideration of the final fermentation temperature and fermentation time of the fermented milk. Examples of microorganisms additionally used in these mixed starters include Lactobacillus gasseri (L. gasseri) and / or Bifidobacterium.

As the mixed starter of the present invention, microorganisms to be inoculated into raw milk can be selected from microorganisms deposited in cell banks and the like. At this time, examples of desirable strains that can be used in the mixed starter of the present invention are as follows. That is, among starters consisting of a mixed culture of microorganisms, Bulgarian bacteria include Lactobacillus delbrueckii subspecies bulgaricus JCM 1002T, Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 (FERM BP-10741), Lactobacillus delbrueckgaricum Streptococcus thermophilus ATCC 19258, Streptococcus thermophilus OLS3059 (FERM BP-10740), Streptococcus thermophilus OLS3294 (NITE P-77).

Examples of the milk fermentation component of the present invention include cheese, yogurt, fermented milk, whey (whey) fermented product, etc. that can be obtained by fermentation of microorganisms as described above. Further, for example, fermented milk (yogurt) to water (whey) ) (For example, Japanese Patent No. 3,179,555). By the way, the protein derived from fermented milk (yogurt) has an amino acid score of 100, and the digestibility of the protein is enhanced by fermentation, and the nutritional value is said to be high. Therefore, in the present invention, among these milk fermentation components, yogurt (fermented milk) is particularly desirable. According to the Ministry of Health, Labor and Welfare's Food Sanitation Law “Ministerial Ordinance on Component Standards for Milk and Dairy Products”, “fermented milk” means “fermented milk or milk containing non-fat milk solids equal to or higher than this with lactic acid bacteria or yeast. , A paste or liquid, or a frozen product thereof ”. Furthermore, it is defined as containing 10% or more of live lactic acid bacteria or yeast and not detecting Escherichia coli, containing 8% or more of non-fat milk solids as its components.
On the other hand, according to the international standard, “Yogurt is a product made from lactic acid fermentation of both Lactobacillus bulgaricus and Streptococcus salivarius subsp. Thermophilus. It is made from dairy products such as skimmed milk powder, and a large amount of the aforementioned two bacteria are alive in the final product.
In the present invention, yogurt includes those specified by both of these definitions. In the present invention, yogurt includes any of yogurt to eat (solid, pasty), drink yogurt (liquid), frozen yogurt (frozen), powder yogurt (powder), and the like. Methods for producing these yogurts are known to those skilled in the art. An example of a method for producing yogurt is as follows: a step of preparing a mixed starter using the aforementioned Lactobacillus delbrueckii subspecies bulgaricus OLL1073R-1 and Streptococcus thermophilus OLS3059; a step of inoculating the mixed starter into raw milk; The process of performing, the process of flavoring, the process of filling a packaging material and a container, etc. will be passed.

The present inventors have found that in humans who have taken at least one component selected from the group consisting of (a) to (c) below, the skin condition is improved, in particular, pigment formation is inhibited. It was. That is, the present invention provides a composition comprising at least one component selected from the group consisting of the following (a) to (c), which is used for oral administration to an animal. Alternatively, the present invention provides a pigment formation inhibitor comprising at least one component selected from the group consisting of the following (a) to (c).
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof The composition of the present invention, or the pigment formation inhibitor, in a preferred embodiment, additionally contains a milk fermentation component Can (including).

The present invention also relates to a method for improving skin condition, comprising the step of orally administering at least one component selected from the group consisting of (a) to (c) below to an animal.
(A) Propionic acid bacteria culture (b) DHNA or analog thereof (c) ACNQ or analog thereof The subject to which the composition of the present invention is administered is a mammal. A mammal is preferably a human.

The present invention relates to the use of at least one component selected from the group consisting of (a) to (c) below in the production of a pigmentation inhibitor in the skin. Alternatively, the present invention relates to the following (a) ~ of at least one component selected from the group consisting of (c), their use in dye-forming inhibition in the skin. In addition, the present invention provides a method for producing a pigmentation inhibitor in skin, comprising the step of blending at least one component selected from the group consisting of the following (a) to (c) with a pharmaceutically acceptable carrier: About.
Furthermore, the present invention comprises at least one component selected from the group consisting of the following (a) ~ (c), relates to the use in the manufacture of a composition for improving skin conditions. Alternatively, the present invention relates to the use of at least one component selected from the group consisting of (a) to (c) below in improving skin conditions.
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof

Alternatively, the present invention includes at least one component selected from the group consisting of the following (a) ~ (c), provides a pharmaceutical composition for improving skin conditions. Furthermore, the present invention relates to the use of at least one component selected from the group consisting of (a) to (c) below in the manufacture of a pharmaceutical composition for improving skin conditions. The pharmaceutical composition of the present invention contains a pharmaceutically effective amount of at least one component selected from the group consisting of the following (a) to (c). The pharmaceutical composition of the present invention can contain a carrier suitable for oral administration. The pharmaceutical composition of the present invention can be administered as a food for the purpose of improving the skin condition.
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof

Alternatively, the present invention provides the following (a) method for improving skin conditions comprising the step of at least one component is administered to the animal is selected from the group consisting of ~ (c).
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof

In the present invention, “improvement of the skin condition” means skin and skin gloss, beam, dullness, pigmentation (stain), sagging, pore conspicuousness, texture, wrinkle, dryness (horny layer moisture content), stickiness, transparent It means that at least one condition selected from the group consisting of feeling, redness, paste on foundation, swelling, bear noticeability, skin rash, moisturizing, and pigmentation is improved. Further, in the present invention, “improvement of skin condition” includes improvement of skin symptoms and suppression of onset due to various allergic dermatitis including atopic dermatitis. Preferred examples of the “improving skin condition” of the present invention include, but are not limited to, improvement of texture density (texture score), increase of stratum corneum water content, and decrease of pigmentation.

There is a texture as an index representing the surface form of the skin. When the skin is observed, fine grooves run like a mesh, and the portion surrounded by the grooves is a triangle, a diamond, or a rectangle. This groove is called a skin groove, and the part surrounded by the skin groove is called a hide hill. In general, when it is said that the skin is fine (high texture density), the crevice is narrow and shallow, and the skin is regularly shaped. Conversely, the wider and deeper the crevice is, the more conspicuous the skin is, and when the skin becomes uneven, the texture of the skin surface is rough and rough (the texture density is low). It becomes skin (Hif Science of Beauty, Revised 8th Edition, Toshiaki Yasuda, Osamu Urushiba Revised, Nanzan-do 2002, Chapter 1, Beautiful Skin, p6). Normal turnover is maintained and the keratinocytes regularly undergo terminal differentiation (keratinization), whereby the shape of the keratinocytes becomes uniform and a healthy stratum corneum with high water retention is formed. This means that the texture is adjusted, and the improvement of the texture means that the texture becomes fine, the texture density (texture score) increases, the texture is adjusted, and the like.

Improvement in texture density can be determined by methods well known to those skilled in the art (Fragrance J., vol35 (2), (2007), Anti-Aging Series No.2 forefront of anti-aging of skin, NT Corporation.・ S (2006). For example, the texture density can be measured by the following method.
-A method of taking a replica of the skin surface using an impression material such as silicon rubber, copying the replica image with a CCD camera, and quantifying the surface shape from image analysis (replica image analysis method).
・ A method to accurately measure unevenness on the replica surface in three dimensions using laser light (replica three-dimensional measurement method).
A method of taking a skin surface image using a video microscope or direct skin analyzer and analyzing the image (skin surface shape image analysis method using a video microscope).
A method of projecting a grid pattern on the skin and obtaining three-dimensional information of the skin from the distortion of the image (three-dimensional direct measurement method without using a replica).
In the present invention, when the texture density is higher than when the composition of the present invention is not used, it can be evaluated (determined) that the texture density is improved. Alternatively, the texture density is compared before and after the administration of the composition of the present invention, and it can be evaluated that the texture density is improved even if the texture density is increased.

The texture score is a numerical value for relatively evaluating texture measured by the Robo Skin Analyzer (In-Forward Co., Ltd.) of the whole face image capturing / image analysis system. In the case of an ideal texture (texture model), the texture score is set to 100, and it is expressed by a numerical value from 0 to 100. More specifically, in a monochrome image of a skin photographed with a microscope, the dark part is a skin groove and the bright part is a skin hill, and the dark part and the bright part are enhanced and binarized, respectively. : 0.4mm) The area that can be judged as a texture model is a numerical value that is relatively expressed by the area ratio with respect to 100 of the constant area of the skin photographed with a microscope. Image processing and image analysis, such as microscopic image capture at the shooting position (shooting range) of the face, monochrome image enhancement processing or texture model judgment, are controlled under certain conditions by the Robo Skin Analyzer device and software. Done.
In the present invention, when the texture score is higher than when the composition of the present invention is not used, it can be evaluated (determined) that the texture score (texture) has been improved. Alternatively, the texture score is compared before and after the administration of the composition of the present invention, and it can be evaluated that the texture score (texture) is improved even if the texture score increases. The improvement in texture score can be said to be an improvement in texture density, that is, an improvement in texture.

The stratum corneum is located on the outermost layer of the skin, and is a layer in which flat keratinocytes are superposed, with keratinized epidermal keratinocytes. The smoothness of the skin is closely related to the moisture content of the stratum corneum, and it is said that the moisture content of the stratum corneum is 15% to 20% in the case of normal skin with a smooth state. The stratum corneum moisture content can be measured by methods well known to those skilled in the art, such as using an image analysis system such as a Corneometer (Anti-Aging Series No. 2 Frontier of Anti-Aging of Skin, NTS Corporation). (2006)). For example, the stratum corneum moisture content can be measured by the following method.
-A method of measuring skin electrical conductivity and capacitance using high-frequency current.
・ Measurement from dielectric relaxation of skin.
・ Method using infrared spectrum.
-Photoacoustic measurement method.
• Magnetic resonance tomography.
-Raman spectroscopy.

Melanin production is known as a cause of pigmentation (stains). Melanin is usually present in the skin and is an important medical and cosmetic factor that plays an important role in protecting the body from the effects of ultraviolet radiation. Melanin is considered to be synthesized via 5, 6-dihydroxyindole, etc. in the pigment cells in the skin tissue, by the action of tyrosinase, where tyrosine changes to dopa and then to dopaquinone. Therefore, the production of melanin can be suppressed by inhibiting the tyrosinase activity. Substances that inhibit tyrosinase activity are useful as the skin condition improving composition of the present invention or as a pigmentation inhibitor in the skin. The inhibitory activity of tyrosinase activity can be measured using, for example, the degree of production of dopaquinone or dopachrome, which is an intermediate of the production of melanin as a black substance, as an index. The degree of production of dopachrome can be measured, for example, from the change in absorbance (475 nm). In such a measurement method, when the absorbance is low, it can be evaluated that the tyrosinase activity is inhibited.

If melanin is synthesized excessively, it will appear black. On the other hand, uneven distribution of melanin on the skin forms spots, freckles and the like. Such pigmentation such as spots and freckles is exacerbated by ultraviolet irradiation. Examples of the promotion of the production of melanin in pigment cells induced by irradiation with ultraviolet rays include information transmitters such as cytokines, chemokines, cell growth factors, and hormones. More specifically, for example, prostaglandins, melanocyte stimulating hormone (α-MSH), endothelin, stem cell factor (SCF), ACTH, IL-1, IL-8, TNF-α and the like are involved. Melanin production can be detected using, for example, mouse B16 melanoma cells. Specifically, mouse B16 melanoma cells (for example, RIKEN, RCB1283) are cultured, and a substance that promotes or inhibits the production of melanin (for example, the composition of the present invention) is added thereto and sufficiently stirred. Incubate in the dark at 37 ° C, remove the supernatant, and measure the absorbance. As a result of the measurement, it can be evaluated that the production of melanin is promoted when the absorbance is increased as compared to before adding the target substance. Conversely, when the absorbance decreases, it can be evaluated that the production of melanin is inhibited.

In the present invention, the reduction in pigmentation can be confirmed by measuring tyrosinase inhibitory activity and melanin production inhibitory activity by the method as described above. Alternatively, the presence / absence and quantity (evaluation of the number, area, and shade) of pigmentation can be measured more directly. As such a method, for example, a method using an image analysis system such as a Robo skin analyzer is well known to those skilled in the art (skin measurement / evaluation on site level-trouble cases / measures-Science & Technology Co., Ltd. (2007 ) Anti-aging series No.2 The forefront of anti-aging of skin, NTS Corporation (2006)).
In the evaluation of pigmentation by image analysis, it is possible to strongly confirm the pigmentation part in the signal component of “BLUE (blue)” among the three elements of the color existing in the color image (RGB). Thus, shading and shape features (number, area) in the monochrome image created using the BLUE signal, it is possible to define the pigmentation. For example, “Small pigmentation” is a continuous area with an area of 0.6mm ² to 1.2mm ² among the parts that can be detected as “slightly dark parts” and “dark parts” in a monochrome image. can do. Or, for example, “large pigmentation” is a continuous region with an area of 1.2 mm ² or more in a monochrome image that can be detected as a “slightly dark part” and a “dark part” compared to the surrounding part. be able to. Further, by using “redness” as an index, for example, acne and erythema can be detected.

The composition of the present invention can be used in the form of pharmaceuticals, foods and drinks, skin cosmetics and the like. For example, the skin condition can be improved by direct administration as a pharmaceutical. When using the composition of this invention as a pharmaceutical, the culture of propionic acid bacteria can be included in various states. For example, it can be contained in the form of a suspension of propionic acid bacteria, a culture of propionic acid bacteria (cells, culture supernatant (including medium components)), a fermented product of propionic acid bacteria, and the like.

The composition of the present invention or the pigmentation inhibitor in skin can contain a culture of propionic acid bacteria as it is. Or it can also contain as a processed product of propionic acid bacteria which processed the culture of propionic acid bacteria with something. Examples of the processed product of propionic acid bacteria used in the composition of the present invention or the pigmentation inhibitor in the skin include, for example, propionic acid bacteria itself, propionic acid bacteria content, concentrated fermented milk, pasted product, and dried product. (At least one selected from spray-dried products, freeze-dried products, vacuum-dried products, and drum-dried products), liquid products, diluted products, and crushed products. Further, as the propionic acid bacteria, live cells, wet bacteria, dry bacteria and the like can be used as appropriate. And as a propionic acid bacterium, dead cells obtained by sterilization treatment (heat sterilization treatment, radiation sterilization treatment, crushing treatment, etc.) can be appropriately used. Furthermore, the pigment formation inhibitor in the composition of the present invention or skin can also be added to pharmaceuticals and / or foods and drinks having biological standards such as infant formula (so-called powdered milk). Moreover, it can apply to various pharmaceuticals and / or food / beverage products by forms other than the form normally used as a pharmaceutical and / or food / beverage products.

The composition of the present invention or the skin pigmentation inhibitor can be orally administered alone or mixed with other components commonly used in pharmaceuticals and foods. At this time, particularly when used in combination with other compounds or microorganisms having an effect of improving the skin condition, it is effective for improving the skin condition in humans and animals. The daily intake of the pharmaceutical composition or food or drink containing the pigment formation inhibitor in the composition of the present invention or skin is not particularly limited because it varies depending on age, symptoms, body weight, use, etc. 10000 mg / kg body weight can be ingested, preferably 0.1 to 1000 mg / kg body weight can be ingested.

On the other hand, in anticipation of improving skin condition, special purpose foods such as foods for specified health use, nutritional functional foods, infant formulas, infant formulas, infant formulas, health functional foods, sick people It can also be ingested as edible foods, dairy products, fermented milk and the like. Furthermore, it can also be ingested as food / beverage products by mix | blending with various food / beverage products regardless of forms, such as liquid form, paste form, powder, and solid form. As foods and beverages, milk, soft drinks, powdered drinks, fermented milk, lactic acid bacteria drinks, acidic drinks, yogurt, cheese, bread, biscuits, crackers, pizza crusts, prepared milk powder, liquid foods, food for the sick, nutritional foods, frozen foods Examples thereof include food compositions, processed foods, and other commercially available foods. When the composition or the pigment formation inhibitor in the skin of the present invention is in the form of an acidic drug or food or drink, the pH can be set to 2.0 to 6.0, preferably 3.0 to 5.0.

When the composition of the present invention or the pigmentation inhibitor in the skin is continuously administered to animals, it can be orally administered as a nutrient, food / drink, food or the like. When the composition of the present invention or the pigmentation inhibitor in the skin is administered as a nutrient, food or drink, food, etc., in addition to the milk fermentation component and the culture of propionic acid bacteria, the nutrients are additionally blended. Its nutritional composition can be adjusted. As the additional nutrient of the present invention, water, protein, carbohydrate, lipid, vitamins, minerals, organic acid, short chain fatty acid, organic base, fruit juice, flavors, and the like can be used. For these nutrients, for example, the following components can be used.

Protein: (animal protein or vegetable protein or their degradation products), whole milk powder, skim milk powder, partially skimmed milk powder, casein, whey, whey powder, whey protein, whey protein concentrate (WPC), whey protein separation (WPI), α-casein, β-casein, κ-casein, β-lactoglobulin, α-lactalbumin, lactoferrin, soy protein, chicken egg protein, meat protein, etc. Milk-derived lipids and saccharides, etc .: butter, whey Minerals, creams, non-protein nitrogen, various milk-derived components such as sialic acid, phospholipids, and lactose Peptides and amino acids: various peptides such as casein phosphopeptide and collagen peptide, various amino acids such as lysine and arginine

Sugars: modified starch (dextrin (maltodextrin, resistant dextrin, etc.), soluble starch, British starch, oxidized starch, starch ester, starch ether, etc.), dietary fiber, fermented glucosamine, reduced maltose, pullulan, etc.

Vitamins: Vitamin A, carotene, vitamin B group, vitamin C, vitamin D group, vitamin E, vitamin K group, vitamin P, vitamin Q, niacin, nicotinic acid, pantothenic acid, biotin, inositol, choline, folic acid, elsorbine Minerals such as acids: Calcium, phosphorus, potassium, chlorine, magnesium, sodium, copper, iron, manganese, zinc, selenium, chromium, molybdenum and other organic acids: Malic acid, citric acid, lactic acid, tartaric acid and other short chain fatty acids: acetic acid , Propionic acid, Butyric acid, Valeric acid, Caproic acid, etc. Fatty acid ester: Glycerin fatty acid ester, Polyglycerin fatty acid ester, Sucrose fatty acid ester, etc. These additional nutrients are derived from chemically synthesized ingredients and natural products Any of the components to be used can be used. And the foodstuff which finally contains the target component can also be mix | blended as a raw material. These components are finally matched to the composition of the nutrient of interest, it can be formulated in combination with at least at least one or two or. The form of the composition may be solid or liquid, and can be prepared in a gel or semi-solid form. Therefore, these nutrients can also be administered orally as a functional food.

In fact, as shown in the examples described later, the composition of the present invention improved the skin condition by ingestion as a composition containing a culture of propionic acid bacteria. Therefore, a functional food containing at least one component selected from the group consisting of (a) to (c) below, or a composition having a composition as a pharmaceutical is one of the preferred embodiments of the present invention. That is, the present invention improves the skin condition including the step of blending at least one component selected from the group consisting of (a) to (c) below into a functional food or a pharmaceutically acceptable carrier. The present invention relates to a method for producing a functional food or a pharmaceutical composition. Alternatively, the present invention provides a method for imparting an ability to improve skin condition to a functional food, comprising the step of blending the functional food with at least one component selected from the group consisting of the following (a) to (c): To do.
(A) Propionic acid bacteria culture (b) DHNA or analog thereof (c) ACNQ or analog thereof Further, the present invention provides a composition for improving skin condition comprising the following nutrients. That is,
Propionic acid cultures Milk fermentation components Sugars, etc.

In the above composition, the culture of propionic acid bacteria is, for example, (i) 1,4-dihydroxy-2-naphthoic acid (DHNA) or an analog thereof, and (ii) 2-amino-3-carboxy-1,4- It can be either naphthoquinone (ACNQ) or an analog thereof, or both. Moreover, when the milk fermentation component in the said composition contains a protein, the protein from which it originates differently as a protein can also be further mix | blended. For example, a milk component can be blended in addition to the milk fermentation component. Each component which comprises the composition of this invention can be suitably adjusted according to various conditions, such as a physique, age, sex, etc. of the object administered as a functional food. More specifically, the following composition (per 100 mL or 100 g) can be shown as a general composition.

That is, 1 mg to 22 g, usually 10 mg to 17 g, preferably 10 mg to 11 g, or 0.01 μg to 15 mg, usually 0.5 μg to 10 mg, preferably 0.5 μg to 0.1 mg in terms of the amount of DHNA may be added as a culture of propionic acid bacteria. it can. In addition, the fermented milk ingredient 0.01 g ~ 100 g, usually 10 g ~ 90 g, preferably 30 g ~ 80 g, more preferably, to 50 g ~ 70 g formulation.
In the present invention, by adding a milk fermentation component, it is possible to improve the palatability of the composition such as flavor and texture. When improving palatability, it is desirable to make most of the composition in the present invention a milk fermentation component. Therefore, for example, in addition to the culture addition amount of propionic acid bacteria illustrated above, it can be set as the composition in this invention by mix | blending a milk fermentation component. Specifically, 1 mg to 22 g of culture of propionic acid bacteria, usually 10 mg to 17 g, preferably 10 mg to 11 g, or 0.01 μg to 15 mg, usually 0.5 μg to 10 mg, preferably 0.5 μg to 0.1 mg in terms of DHNA 1 g to 100 g, usually 30 g to 100 g, preferably 50 g to 100 g, more preferably 60 g to 100 g of a milk fermentation component can be blended. Further, saccharides can be added in an amount of 0.1 to 20 g, usually 0.3 to 15 g, preferably 0.6 to 10 g.
In the above composition, when a culture of propionic acid bacteria containing DHNA is blended, the amount of the culture can be blended so as to have the above composition in terms of DHNA.

The composition of the present invention may additionally contain at least one nutrient selected from the group consisting of vitamins, peptides, minerals, organic acids or short-chain fatty acids, fatty acid esters and organic bases. Alternatively, for the purpose of improving the taste and aesthetics, a fragrance, sweetener, acidulant, colorant, or the like can be blended. Furthermore, known ingredients that are known to have an effect of improving the skin condition can be additionally blended. For example, coenzyme Q10 and its derivatives are said to improve the skin condition by oral administration. The composition in the case of blending these components can be appropriately adjusted according to various conditions such as the physique, age, and sex of the subject to be administered as a functional food or pharmaceutical composition. More specifically, the following composition (per 100 mL or 100 g) can be shown as a general composition.
Vitamins: 0-20g, usually 0-10g, preferably 0-1200mg
Minerals: 0-5g, usually 0-3g, preferably 0-2g
Organic acid or short chain fatty acid: 0-5g, usually 0-3g, preferably 0-2g
Fatty acid ester: 0 to 10 g, usually 0 to 5 g, preferably 0 to 3 g.
That is, this invention provides the manufacturing method of the functional foodstuff or pharmaceutical composition for improving a skin state including the process of mix | blending the said nutrient with said composition. The functional food or pharmaceutical composition produced according to the present invention can indicate that the intake of the functional food or pharmaceutical composition promotes improvement of the skin condition in the subject.

The following vitamins can be shown as vitamins for blending into the functional food or pharmaceutical composition of the present invention. These vitamins can also contain a pharmaceutically acceptable salt. That is,
Vitamin A,
B vitamins such as vitamin B1,
Vitamin C (ascorbic acid) and its sodium salt (sodium ascorbate)
Etc.
Moreover, the saccharide | sugar for mix | blending with the functional food of this invention or a pharmaceutical composition can be selected from a polysaccharide or a monosaccharide. In addition to water-soluble saccharides, insoluble saccharides can also be blended. More specifically, at least one saccharide selected from the group consisting of the following saccharides or a derivative thereof can be blended.
Examples of monosaccharides include glucose (glucose), mannose, and xylose. Examples of disaccharides include sucrose (sucrose, sugar), lactose (lactose), maltose, trehalose, and palatinose (isomaltulose). the oligosaccharide, fructo-oligosaccharide has a galacto-oligosaccharide, etc. Examples of the polysaccharides, starch, dextrin, and the like. As the sugar alcohol, xylitol, sorbitol, maltitol, lactitol, reduced palatinose, and the like.

The pharmaceutical composition of the present invention can be prepared by blending at least one component selected from the group consisting of (a) to (c) below, for example, with a pharmaceutically acceptable carrier.
(A) culture of propionic acid bacteria (b) DHNA or analog thereof (c) ACNQ or analog thereof In addition, when additional ingredients are blended, the above-mentioned saccharides and the like are used as a carrier and mixed homogeneously. Prepare. Usually, the composition is preferably so that the milk-fermented component and the protein derived from the culture of propionic acid bacteria have a ratio of about 1% or more of the saccharide in the composition, for example, a ratio of about 30% or more. It can be prepared so as to have a ratio of 70% or more of the saccharides therein, more preferably about 100%. When the composition of the present invention is prepared as a pharmaceutical composition, it is desirable to adjust it to be 0.1 to 3 kcal, preferably 0.7 to 2 kcal per mL. Moreover, at the time of mixing, at least 1 or more of the additional component which consists of vitamins and minerals and also dietary fiber can also be added. Dietary fiber is divided into water-soluble dietary fiber and insoluble dietary fiber, and both can be used. Specifically, examples of the water-soluble dietary fiber include the following components. That is, pectin (protopectin, pectinic acid, pectinic acid), gum arabic, guar gum hydrolyzate, glucomannan, galactomannan, psyllium, corn fiber, alginic acid, alginic acid degradation product, carrageenan and the like.

The functional food or pharmaceutical composition of the present invention can be supplied in a liquid, semi-solid or dry state. Semi-solid forms include pastes such as yogurt and gels. For example, a paste-like composition can be obtained by blending a thickener such as pectin. Alternatively, when solidified with gelatin or agar, a gel-like composition can be obtained. Furthermore, the composition can be dried and processed into a powder form or a tablet. The composition in a dry state can be taken as it is or after being dispersed or dissolved in water or milk. Powdered or tablet-like compositions can be taken as they are. Moreover, it can also be ingested by making it contain in confectionery, such as a gummy candy and a tablet confectionery.

Furthermore, the composition of this invention can also be utilized with the form of cosmetics. The cosmetic according to the present invention contains 0.01 to 10%, preferably 0.05 to 5% (as dry weight) of the propionic acid bacteria culture and / or processed product of the present invention as an active ingredient, and is commonly used for this. By adding a cosmetic base, it can be formulated into a solid, semi-solid or liquid form according to a conventional method to obtain a general cosmetic or a skin cosmetic.
The cosmetics according to the present invention include various optional ingredients (oil agents, moisturizers, thickeners, preservatives, emulsifiers, pigments, pH adjusters) used in normal cosmetics, external preparations for skin, quasi drugs, pharmaceuticals, etc. Agents, medicinal ingredients, ultraviolet absorbers, fragrances, etc.) can be appropriately blended. And the cosmetics which concern on this invention can be manufactured according to a conventional method.

The cosmetic of the present invention generally cosmetics, is not limited to skin cosmetics, quasi drugs, may be an externally applied drugs and the like. The dosage form can also be arbitrarily selected according to the purpose, such as cream, emulsion, foundation, pack, lotion, gel, solution, and stick. When used as a cosmetic for the purpose of whitening, anti-inflammatory, anti-oxidation, moderate moisture absorption and moisture retention, the necessary amount may be applied several times as appropriate.
The skin cosmetics according to the present invention can be skin lotions, creams, emulsions, packs and other skin cosmetics. In the skin cosmetic according to the present invention, an appropriate amount (for example, 0.001% to 15%), preferably 0.001% to 15% of an active ingredient (existing whey mineral) as a base, auxiliary agent or the like commonly used in skin cosmetics according to a conventional method, 0.01% to 10% can be blended. Since the active ingredient is derived from food, there is essentially no problem with toxicity. Since the skin cosmetic according to the present invention is externally applied to the skin, safety is particularly important.

Among the skin cosmetics according to the present invention, the skin lotion can be prepared as follows. For example, humectants such as glycerin, propylene glycol, and citric acid, pH adjusters, and the like are dissolved in purified water. In addition, surfactants, preservatives, fragrances and the like are dissolved in alcohol. A general lotion can be produced by mixing and solubilizing both. Toner lotion can contain 0.01% to 10% of the active ingredient of the present invention (such as a culture of propionic acid bacteria) in the aqueous phase.
The cream can be prepared as follows. For example, the aqueous phase and oil phase were prepared, by heating the respective resulting aqueous phase and oil phase mixture is stirred, may be prepared by emulsifying. The aqueous phase part can be prepared by adding a hydrophilic component to purified water. Examples of the hydrophilic component include humectants such as glycerin and sorbit, but are not limited thereto. The oil phase part can be prepared by mixing a solid oil component, a liquid oil component, and an oil component. Examples of the solid oil include, but are not limited to, the following. That is, beeswax, paraffin, microcrystalline wax, ceresin, higher fatty acids and the like. Examples of the liquid oil include, but are not limited to, the following. That is, squalane, liquid paraffin, various ester oil components and the like. In a general cream, an active ingredient (such as a culture of propionic acid bacteria) can be contained at 0.01 to 10% in the aqueous phase.

The emulsion can be prepared as follows. For example, it can be prepared by preparing a water phase part and an oil phase part, emulsifying, and adding a thickener thereto. The aqueous phase part can be prepared by adding a humectant such as glycerin or 1,3-butylene glycol to purified water and mixing with heating. On the other hand, the oil phase part can be prepared by adding oily components such as preservatives and surfactants to the solid oil, semi-solid oil and liquid oil.
Examples of the solid oil include, but are not limited to, beeswax and paraffin. The semi-solid oil content is not limited to those including petrolatum, lanolin and the like. Examples of the liquid oil include, but are not limited to, squalane, liquid paraffin, various ester oils, and the like. Examples of the thickener include, but are not limited to, carboxyvinyl polymer and carboxymethyl cellulose. In the production of a general emulsion, the active ingredient of the present invention is added to the aqueous phase so as to be 0.01% to 10% to obtain an emulsion.

The pack can be prepared as follows. For example, moisturizing agents in purified water, allowed to swell by adding a coating agent, etc. are added kaolin, talc, powders of titanium oxide if necessary to this. Furthermore, the ethanol which melt | dissolved the fragrance | flavor, the preservative, etc. is added, and it knead | mixes until it becomes paste-form.
Examples of the humectant include, but are not limited to, glycerin and sorbit. Examples of the film agent include, but are not limited to, polyvinyl alcohol and polyvinyl pyrrolidone. In the production of a general pack, the active ingredient of the present invention is added so as to be 0.01% to 10% to make a pack.

In the present invention, if necessary, an antiseptic can be added. A preservative generally used as a preservative for cosmetics can be blended in the cosmetic of the present invention. Specifically, examples of the preservative include the following. That is, paraoxybenzoic acid ester, phenonip (paraben phenoxyethanol solution), phenoxyethanol, phenol, resorcin, hinokitiol, benzoic acid or its salt, salicylic acid or its salt, sorbic acid or its salt, hexachlorophene, benzalkonium chloride, phenols , acids, halogenated bisphenols, amides, quaternary ammonium compounds, various fungicides such as are commonly used in detergent such cosmetics industry.
Paraoxybenzoates are also referred to as parabens. Parabens include, but are not limited to: That is, methyl paraben, ethyl paraben, propyl paraben, butyl paraben and the like.

In the present invention, the lotion obtained as described above can be used as it is. Moreover, the processed material can also be used. Examples of processed products include (reduced pressure) concentrates, pasted products, dried products (spray dry, freeze dry, etc.), diluted products, and the like. Or the said lotion and its processed material can also be addition-blended with various cosmetics as a raw material compounding component of cosmetics.

In a preferred embodiment, the composition or pigment formation inhibitor of the present invention can be in the form of a tablet. That is, the present invention relates to a skin condition improving composition molded into a tablet. Or this invention relates to the pigmentation inhibitor in the skin shape | molded by the tablet. A tablet generally refers to a solidified product obtained by adding an active ingredient or an active ingredient to an excipient to a certain shape by a method such as compression molding. Tablet molding methods are well known to those skilled in the art, and can be molded using, for example, a known tableting device. The tablet of the present invention can be chewable or non-chewable, but non-chewable is preferred.

* The size and weight of the tablet can be designed as appropriate according to its intake form. As an example, when swallowing without chewing with water or beverage, the diameter can be, for example, 10 mm or less, but is not limited thereto. Alternatively, in the case of a tablet confection that enjoys flavor by chewing, the diameter can be 25 mm or less, but is not limited thereto. The size of the tablet is, for example, 1 mm or more and 25 mm or less, and preferably 5 mm to 15 mm in diameter. The weight is, for example, 10 to 5000 mg, preferably 100 to 1000 mg.

The hardness of the tablet can be appropriately designed according to the intake form, and is preferably 2 kgf or more and 5 kgf or less. If it is less than 2 kgf, the binding force is small and the tablet shape cannot be maintained. On the other hand, if it exceeds 5 kgf, disintegration in the stomach will be worse when eating.

In addition to the propionic acid bacteria culture as an active ingredient, the tablet of the present invention contains excipients, fluidizers, proteins, lipids, sugars, peptides and amino acids, vitamins, esters, fruit juices, pigments, flavors, and the like. Can be included. Examples of the compounding amount of these substances include, but are not limited to, the following values with respect to 200 parts by weight of the propionic acid bacteria culture.
Peptides and amino acids: For example, 500 to 200,000 parts by weight, preferably 500 to 1000 parts by weight Sugars: for example, 0.1 to 100 parts by weight, preferably 1 to 50 parts by weight Esters: for example, 0.1 to 100 parts by weight, preferably 1.0 to 50 parts by weight, more preferably 10 to 30 parts by weight Fruit juice: for example 0.01 to 500 parts by weight, preferably 0.1 to 100 parts by weight, more preferably 1 to 50 parts by weight Dye: for example 0.01 to 500 parts by weight , Preferably 0.1-50 parts by weight, more preferably 1-10 parts by weight perfume: for example 0.01-500 parts by weight, preferably 0.1-100 parts by weight, more preferably 1-50 parts by weight

Flavor can be imparted to the tablet by adding fruit juice to the tablet. In the present invention, fruit juices well known to those skilled in the art such as fruit juice and mint juice can be used. Examples of fruit juices include orange juice, orange juice, lemon juice, grapefruit juice, grape juice, apple juice, banana juice, pear juice, pineapple juice, fruit mix juice, etc., but are not limited thereto. . Examples of the mint juice include peppermint juice, spearmint juice, peach mint juice, grapemint juice, orange citrus mint juice, apple mint juice, hascup mint juice, cherry mint juice, pineapple mint juice, and the like. It is not limited to these. As the fruit juice of the present invention, either natural fruit juice or artificially synthesized fruit juice can be used.

As a pigment,
Anato pigment (Anato, carotenoid, carotenoid pigment, carotenoid, carotenoid pigment),
Turmeric pigment (curcumin, turmeric pigment),
Caramel I, Caramel II, Caramel III, Caramel IV (Caramel, Caramel Color),
Imamo carotene, Dinariella carotene, carrot carotene, etc. (extracted carotene, carotene pigment, carotenoid pigment),
Gardenia blue pigment, gardenia red pigment, gardenia yellow pigment (gardenia, gardenia pigment),
Cochineal dye (carminic acid dye, carminic acid, cochineal),
Food tar dyes (food red 2, food red 3, food red 40, food red 102, food red 104, food red 105, food red 106, food yellow 106, food yellow 4, food yellow 5, Edible Green No. 3, Edible Blue No. 1 and Edible Blue No. 2),
Copper chlorophyll, copper chlorophyllin sodium,
Benikouji pigment (monascus pigment, red yeast rice, monascus)
Safflower red pigment (Casamas red pigment),
Safflower yellow (Casamas yellow)
However, the present invention is not limited to these.

Moreover, a fragrance | flavor can use a thing well-known to those skilled in the art. For example, citrus flavor (orange, lemon, grapefruit juice), fruit flavor (pineapple, strawberry, melon, banana, etc.), milk flavor (milk, butter, yogurt, etc.), coffee, cocoa, chocolate flavor, tea Fragrance (Black tea, Matcha, Green tea, etc.), Vanilla flavor, Mint flavor (Peppermint, Spearmint, etc.), Spice flavor (Shiso, Ginger, Cinnamon, Wasabi, etc.), Nut flavor (Peanuts, Almonds, Marron, etc.), Meat・ Seafood flavors (beef, pork, chicken, crab, shrimp, bonito, etc.), vegetable flavors (tomato, corn, onion, etc.), Western flavors (whiskey, brandy, wine, rum, etc.), seasoning flavors (sauce) , Soy sauce and the like), but is not limited thereto. Moreover, as a form of a fragrance | flavor, it can be set as a form well-known to those skilled in the art, such as a water-soluble fragrance | flavor, an oil-soluble fragrance | flavor, an emulsified fragrance | flavor, and a powder fragrance | flavor.
Moreover, light anhydrous silicic acid (silicon dioxide) is mentioned as a fluidizing agent. The blending amount of the fluidizing agent per tablet is 0.5% to 3%, preferably 0.5% to 2.0%.
Further, shellac or the like may be sprayed to coat the tablet after tableting.

The composition or pigment formation inhibitor molded into the tablet of the present invention can stably contain DHNA. The composition or the pigment formation inhibitor of the present invention can obtain the following effects by adopting a tablet form. In other words, it is easy to carry, easy to ingest, can be ingested in a certain amount (ease of optimizing and standardizing the amount used), easy to identify by appearance compared to powders, etc. Adjustments are possible, and effects such as masking of taste can be expected by coating the surface.
In addition, all prior art documents cited in the present specification are incorporated herein by reference.

EXAMPLES Hereinafter, although this invention is demonstrated further more concretely based on an Example, this invention is not limited to a following example.
[Example 1] Evaluation test of effects of Profec (propionic acid bacteria culture) on skin function improvement and intestinal regulation
1. Subject (selection criteria)
Women aged 20 to 39 years with chronic constipation (defecation days average 4 days or less per week) and dry skin.
(Exclusion criteria)
(1) Pregnant women and those who are breastfeeding (2) Those who regularly use constipation medicine (taken every time constipation)
(3) People with atopic dermatitis (4) Those who have severe heart / renal / liver disorder, respiratory disease, cardiovascular disease, etc. and are considered inappropriate to incorporate (5) Those who have allergies to milk (6) Any other person who is judged inappropriate by the doctor in charge of the examination or the doctor in charge of the examination (number of selected persons)
A total of 3 groups of placebo and 2 test meals: 32 in each group, 96 in total

2. Information about test meals
(1) Test meal / acid drink (placebo) (Test meal A)
・ Profec-containing acidic beverage (test meal B)
・ Profec-containing yogurt drink (test meal C)
(Test meal A) "Acid drink" (placebo)
It is an acidic beverage with pectin, lactic acid, yogurt flavor, vitamin C and aspartame added to water, and does not contain milk components or lactic acid bacteria.
(Test meal B) "Profec-containing acidic beverage"
An acidic beverage obtained by adding Profec (propionic acid bacteria culture) at 1% to the above-mentioned “acidic beverage” and does not contain milk components other than Profec and lactic acid bacteria.
(Test meal C) "Profec-containing yogurt drink"
The yogurt base mix was inoculated with Lactobacillus bulgaricus 2038 strain and Streptococcus thermophilus 1131 strain isolated from “Meiji Bulgaria Yogurt” (trade name) manufactured by Meiji Dairies Co., Ltd. (currently Meiji Co., Ltd.) and fermented to prepare yogurt. The yogurt (60%), the components added to the “acidic beverage” and sugar were added, and Profec (culture of propionic acid bacteria) was further added at 1% to prepare a yogurt beverage. The yogurt beverage contains milk components and lactic acid bacteria.
(Profec manufacturing method)
Profec (culture of propionic acid bacteria) is fermented after being fermented with propionic acid bacteria (P. freudenreichii ET-3 strain) obtained by separating milk raw material (whey) from emmental cheese.

(2) Storage conditions The test meal was stored refrigerated at 10 ° C or lower.
(3) Test food intake Profec (culture of propionic acid bacteria) was added to one test drink (120 mL) so that the amount was 6.6 μg / day in terms of DHNA.
(4) Ingestion frequency The test meal was ingested once a day (120 mL) for 4 weeks. Test meal intake (morning, noon, evening, before meals, and after meals) was voluntary by subjects.

3. Test method
(1) Study design : Double-blind placebo control study Group composition: Placebo diet group, 2 groups of test diet groups, 3 groups, 32 patients in each group, 96 patients in total
(2) Subject assignment test The controller assigned subjects to three groups. At that time, the test treating physician noted that does not occur bias as possible to the result of determination based on the criterion of facial skin findings.
(3) Test schedule Skin test, blood collection, and stool collection were performed before taking the test meal. The test meal was ingested for 4 weeks, and then skin examination, blood collection, and stool collection were performed again.

(4) Skin observation / evaluation items After the subject was in a constant temperature and humidity room (temperature 20 ± 1 ° C., humidity 42.0 ± 2%) for 15 minutes after washing the face, the following items were observed and evaluated.
1) Facial skin findings (entire surface)
(Dry, scales, papules, face blisters, pustules)
2) Facial skin measurement (equipment measurement: cheek)
(Chorn layer moisture content, oil content, transepidermal moisture transpiration, elasticity, pH)
3) Facial skin analysis (image analysis: full surface)
(Kimescore / pigmentation)
4) Corneal layer sampling by tape stripping (inner forearm)
(Measurement of ceramide level and cytokines IL-1ra / IL-1α, IL-8, TNF-α)
5) Completion of questionnaire regarding skin condition (before and after taking test meal)
6) Stool flora analysis (Bifidobacteria count, Bacteroides count)
7) Amount of spoilage stool (indole, p-cresol, phenol, skatole)
Skin analysis was performed at Inforward Co., Ltd. Measurement of the amount of ceramide / cytokine in the stratum corneum sample by tape stripping, fecal flora analysis, and measurement of the amount of spoilage rot products were performed at Meiji Dairies Co., Ltd. (currently Meiji Co., Ltd.).

(5) (from the test start date to the end of 4-week study diet period) prohibited or restricted in matters test period, it was prohibited or limited to the following matters.
1) To take new therapeutic drugs for cosmetic purposes and to use external drugs on the observation site. However, continuous use was permitted if it was conducted before the start of the test.
2) Treatment such as chemical peeling, laser treatment, phototherapy to the observation site for cosmetic purposes.
3) Taking supplements newly.
4) Ingestion of foods containing lactic acid bacteria other than test meals (yogurt, fermented milk, etc.) and foods containing oligosaccharides However, continuous use was allowed when supplements (amino acids, vitamins, etc.) were regularly used.

4). Evaluation method The multiple comparison test (Tukey-Kramer method) between three groups in the amount of change (rate) before and after intake and the intra-group comparison test before and after intake.
Specifically, for discrete data (score, number of times, data expressed in number), perform “Wilcoxon signed rank sum test”, and for continuous data (measured value), the result of normality test of each data Based on the above, a “corresponding t-test” or “Wilcoxon signed rank sum test” was performed.
(Skin function evaluation)
・ Change in stratum corneum moisture ・ Change in oil content ・ Change in transepidermal water loss (TEWL, also called transepidermal water loss) ・ Change in elasticity ・ Change in texture score ・ Pigmentation (number ・Area) ・ Change in pH ・ Questionnaire survey on skin condition (changes before and after ingestion)
· Corneum ceramide cytokines (IL-1ra / IL-1α, IL-8, TNF-α) of variation (facial skin measuring: instrumental measurement)
・ Corn layer moisture: Corneometer CM825 (Courage + Khazaka electronic GmbH)
・ Oil content: Sebumeter SM810 (Courage + Khazaka electronic GmbH)
・ Transepidermal water transpiration: VapoMeter (Delfin Technologies)
・ Resistance: Cutometer MPA580 (Courage + Khazaka electronic GmbH)
・ PH: Skin PH-meter PH900 (Courage + Khazaka electronic GmbH)
(Intestinal regulation evaluation)
・ Changes in stool flora (Bifidobacterium, Bacteroides) ・ Measurement of stool decay products (phenol, p-cresol, indole, skatole)
・ Changes in the number of defecation days (diary)

5). result
(1) Cases subject to statistical analysis A total of 86 cases including 30 subjects on the test meal A intake group, 28 subjects on the test food B intake group, 28 subjects on the test food C intake group a) excluded cases before the analysis Patients who had never visited the hospital since the visit or who had dropped out due to the non-cooperation of the subjects were judged as dropped. In addition, the non-intake date in the test diet period is determined to fall off a case that has reached to 10% of the total intake days (probability). In this example, 6 cases (test food A intake group: 2 people, test food B intake group: 2 people, test food C intake group: 2 people) were dropped out and excluded from the analysis.
b) Discontinuation example In this example, one person who became pregnant during the study period (test food B intake group) was regarded as a discontinuation case and excluded from the analysis.
c) Drugs that may affect the intestinal flora in 3 cases (test food B intake group: 1 person, test food C intake group: 2 persons) that had matters that were thought to affect the test results Was excluded from the assessment (2 cases of intestinal use: 1 case, antibiotic use: 1 case).

(2) Intragroup time-dependent comparison of skin measurement results For each measurement item, “corresponding t-test” or “Wilcoxon signed ranking” between the measurement results at the start of the test and after intake for 4 weeks for each group A “sum test” was performed.
-Test meal A (placebo) intake group Transepidermal water transpiration, viscoelasticity, and skin pH were significantly improved.
-Test meal B (Profec-containing acidic beverage) intake group The stratum corneum water content, viscoelasticity, and skin pH were significantly improved.
-Test meal C (Profec-containing yogurt drink) intake group The stratum corneum water content, viscoelasticity, and skin pH were significantly improved.
The comparison result of the stratum corneum moisture content before and after each test meal contact is shown in FIG. In the test food B and C intake groups, the stratum corneum water content was significantly improved compared with that before contact (p <0.05). In contrast, no significant improvement in stratum corneum water content was observed in the test meal A intake group that did not contain Profec.

The capacitance measurement method was used for the measurement of the stratum corneum moisture content. Courage + Khazaka electronic GmbH's Corneometer (registered trademark) makes use of the fact that the dielectric constant of water is significantly different from that of other substances. ) To indirectly calculate the stratum corneum moisture content. The unit is expressed in terms of horny moisture (arbitrary unit; AU) (skin measurement / evaluation at site level-trouble cases / measures-Chapter 8 of Science & Technology Co., Ltd. (2007)).

(3) Comparison of skin measurement results between groups The skin measurement results Δ of each group (starting measured value—measured value after 4 weeks) were compared between groups.
As a result, compared with the test meal A (placebo) intake group, the test meal B (Profec-containing acidic drink) intake group and the test meal C (Profec-containing yogurt drink) intake group improved significantly in the stratum corneum moisture content.

(4) Intragroup time-lapse comparison of image analysis results For each group, “corresponding t-test” or “Wilcoxon signed ranking” between the analysis results at the start of the test and after intake for 4 weeks for each group A “sum test” was performed.
(Small pigmentation: 0.6 to 1.2 mm ² , Large: 1.2 mm ² or more, I to III: Pigment concentration I <II <III)
・ Test meal A (placebo) intake group Pigmentation size II (number / area) significantly deteriorated.
・ Test food B (Profec-containing acidic beverage) intake group The texture improved significantly.
-Test food C (Profec-containing yogurt drink) intake group Texture, pigmentation large II (number), large III (number) improved significantly.
The comparison result of texture score before and after each test meal intake is shown in FIG. Test diet B, the C intake group, compared to the previous ingestion Kimesukoa significantly improved (p <0.05). In contrast, the texture score worsened in the test meal A intake group that did not include Profec.
The texture score is a binary image obtained by emphasizing the dark part of the bright part and the dark part of the dark part of the monochrome image of the whole face image capturing and image analysis system (Robo Skin Analyzer, Inforward Co., Ltd.). As a result, the average of the upper and lower cheeks (with the cheekbones set on the cheeks) was determined with an equilateral triangle texture model with a side of 0.4 mm as 100.

(5) Comparison between groups of image analysis results Comparison between groups was performed on the image analysis results Δ (starting measurement value−measurement value after 4 weeks) of each group.
The texture was significantly improved in the test meal B (Profec-containing acidic beverage) intake group and the test meal C (Profec-containing yogurt drink) intake group compared to the test meal A (placebo) intake group. In addition, about pigmentation large II (number), large III (number), large II (area), compared with test food A (placebo) intake group, test food C (Profec-containing yogurt drink) intake group significantly Improved.

(6) Questionnaire survey results A questionnaire survey on skin over 19 items was conducted before and after ingestion. Based on the results of scoring for each item, a “Wilcoxon signed rank sum test” was performed before and after ingestion. List items that improved significantly in each group.
・ Test food A (placebo) ingestion group Tsuya, amber, dullness, sagging, dryness, foundation paste, swelling 7 items in total ・ Test meal B (Profec-containing acidic beverage) ingestion group Tsuya, acupuncture, dullness, blotches, conspicuous pores, Texture, wrinkles (mouth), dryness, stickiness, transparency, foundation paste, bear total of 12 items / test food C (Profec-containing yogurt drink) intake group gloss, glue, dullness, sagging, wrinkles (forehead), wrinkles (eye area) ), Dryness, transparency, foundation paste, swelling 10 items in total

(7) Comparison between groups of questionnaire survey results Comparison between groups was performed on the questionnaire survey results Δ of each group (survey score after 4 weeks-starting survey score).
As a result, regarding the stickiness, the test meal B (Profec-containing acidic beverage) intake group was significantly improved as compared with the test meal A (placebo) intake group. In addition, regarding wrinkles (forehead), the test food C (Profec-containing yogurt drink) intake group significantly improved compared to the test food A (placebo) intake group.

(8) Comparison of the number of defecations within the group over time The average number of defecations during the two weeks before ingestion and the average number of defecations during the ingestion period were compared by “Wilcoxon signed rank sum test”.
・ Test food A (placebo) intake group Defecation frequency 3.7 ± 1.2 → 4.7 ± 2.3
・ Test food B (Profec-containing acidic beverage) intake group Defecation frequency 3.6 ± 1.2 → 4.3 ± 1.6 (significantly improved)
・ Test food C (Profec-containing yogurt beverage) intake group Defecation frequency 3.9 ± 1.0 → 5.0 ± 1.9 (significantly improved)
A comparison result of the number of defecations before and after intake of each test meal is shown in FIG. In the test food B and C intake groups, the number of defecations was significantly improved compared to before intake (p <0.05). In contrast, no significant improvement in the number of defecations was observed in the test meal A intake group that did not contain Profec.
(9) Comparison of defecation frequency between groups A comparison was made between groups regarding the change in defecation frequency Δ of each group (average defecation frequency for 2 weeks before ingestion-average defecation frequency during ingestion period).
As a result, there was no significant difference between the three groups.

[Example 2] Measurement of stratum corneum cytokine
It is known that an exposed part such as a measurement target face is in a weakly inflammatory state as compared to a non-exposed part hidden in clothes. Therefore, a stratum corneum sample was collected by tape stripping, and inflammatory cytokines (IL-1α, IL-1ra, IL-8, TNF-α) in the stratum corneum were measured. In particular, it has been reported that IL-1ra / IL-1α is increased in exposed areas, UV irradiation sites, and atopic dermatitis lesions. Therefore, these cytokines were evaluated as indicators of the inflammatory state of the skin. IL-8 and TNF-α are known to be associated with acne and spots.

Measurement method Collected tape (PPS tape 2.5 x 4 cm, 3 sheets) is cut into small pieces, placed in an Eppendorf tube (2 mL) containing 0.1 mL of PBS containing 0.1% Tween 20, and sonicated (on ice). It was. Soluble protein is eluted from the tape into PBS by sonication (15 minutes). After extraction, the tape was taken out and centrifuged (15000 × g, 1 minute, 4 ° C.) to obtain 1 mL of supernatant. The protein concentration in the supernatant was measured by Micro BCA protein assay, and cytokines (IL-1α, IL-1ra, IL-8, TNF-α) were measured. IL-1α and IL-1ra were proportioned, and IL-8 and TNF-α were corrected by protein amount.

Results There was no difference in the IL-1ra / IL-1α ratio before and after ingestion regardless of the test meal (FIG. 4). The rate of increase after ingestion (after ingestion / before ingestion) relative to before ingestion was the smallest in the test food C (Profec-containing yogurt drink: Profec + Yo) intake group. IL-8 in the stratum corneum was significantly increased before and after ingestion of test meal A (placebo) (FIG. 5, p <0.05, Wilcoxon signed rank sum test). There was no change in IL-8 concentration before and after intake in groups other than the test food A (placebo) group. They were compared between groups among the three groups for the rate of increase in IL-8 (after intake / ingestion before), but statistically significant difference was observed. Many people did not detect TNF-α, and there was no significant difference between the groups in terms of production and increase rates before and after intake (data not shown). During the study period, the increase in ultraviolet rays due to seasonal changes may have affected the increase in stratum corneum IL-8 in the test meal A (placebo) intake group. On the other hand, no significant change in IL-8 was observed in the test food B (Profec-containing acidic beverage) intake group and the test food C (Profec-containing yogurt drink) intake group. This suggested the possibility of suppressing inflammation due to seasonal changes.

[Example 3] Microflora analysis
The purpose of this study was to analyze the changes in the number of Bifidobacterium and Bacteroides spp. In fecal samples submitted to the subjects before and after the test period. More specifically, it was examined whether an increase in the number of Bifidobacterium spp. Or a relative decrease in the number of Bacteroides spp.

Materials / Method After the feces were dissolved at room temperature and uniformly mixed, 20 mg was taken into a tube, mixed with 700 μL of ASL reagent, and allowed to stand for a while. This was vigorously shaken using a tissue lyser (QIAGEN) for 15 minutes under the condition of 2500 rpm. Subsequently, it was immersed in a 70 ° C. hot water bath for 10 minutes and then centrifuged at 15000 rpm for 10 minutes. The supernatant was collected in a separate tube, put Inhibit EX, immediately vortexed for 1 minute, and centrifuged at 15000 rpm for 3 minutes. Thereafter, the supernatant was collected and further centrifuged at 15000 rpm for 3 minutes to obtain a crude nucleic acid purified solution.
This solution was set in a QIA cube (QIAGEN), a DNA purified solution was extracted by automatic operation with a machine, and a 10-fold diluted solution was used as a PCR template.
ABI 7300 real-time PCR System was used for analysis of 16S rDNA amount. Use B.longum standard strain (OLB6125) for Bifidobacterium standard samples and DNA solution extracted from B. vulgatus standard strain (OLB7086) for Bacteroides standard samples, and calculate the number of bacteria using 10 ⁵ cells / g as the detection limit. did.

Results Bifidobacterium and Bacteroides genus counts (cfu / g) were analyzed for 176 stool samples before and after the test period of all 88 subjects, and were divided into groups and compared. Significant difference tests were performed for the difference between placebo and each group at 0 and 4 weeks, and the difference between

weeks

0 and 4 in each group. As a result, there was no significant difference in the number of bacteria in any of the genera Bifidobacterium and Bacteroides. The test meal A (placebo) group is n = 29, the test meal B (Profec-containing acidic drink: profec) group is n = 29, and the test meal C (Profec-containing yogurt drink: profec + yogurt) group is n = 30. is there.

Next, the number ratio of the genus Bifidobacterium and the genus Bacteroides (Bifidobacterium genus / Bacteroides genus) was compared. However, there was no significant difference.
Furthermore, subjects were divided into layers according to the number of Bifidobacterium spp. The results are shown below.
( I ) When only the test subjects whose number of bacteria at the start of the test was 10 ¹⁰ cfu / g or less were extracted, the number of Bifidobacterium spp. Tended to increase in the Profec intake group (p = 0.058).

( Ii ) When only subjects with a bacterial count of 10 ¹⁰ cfu / g or more were extracted at the start of the test, the number of Bifidobacterium spp. Decreased significantly in the placebo-intake group (p = 0.013). On the other hand, there was no significant difference in the number of bacteria in the Profec intake group.

From the above analysis results, it is suggested that Profec may have the effect of suppressing the decrease in people with a large number of initial bifidobacteria and increasing it in people with a relatively small number of initial bifidobacteria It was done. In addition, after classifying the subjects according to the number of initial bacteria, the ratio of the number of Bifidobacterium to the number of Bacteroides was analyzed for each layer. However, there was no significant difference between each layer in any group.

The experimental results of Examples 1 to 3 will be considered below.
1. Profec intestinal regulation In the evaluation of intestinal regulation, no significant change was observed in the placebo group when comparing the number of bowel movements before and after ingestion. However, in the Profec intake group, a significant increase in the number of bowel movements was observed, and an improvement in the intestinal action was observed. In addition, in subjects whose bifidobacteria count in the stool was small before ingestion, a tendency to increase the number of bifidobacteria by Profec intake was observed. Thus, a certain intestinal regulating effect was recognized by Profec ingestion.

2. Influencing factors of seasonal change (change in placebo intake group)
This example was carried out from February to April, and the season shifted from winter to spring during the test period. From winter to spring, the season changes greatly (temperature / humidity increase, UV light increase), and turnover of stratum corneum cells is often modulated. In general, it is recognized by women that spring is a season with many skin problems. Therefore, the influence of seasonal variation on the test results in this example will be described from the change in the placebo intake group.

2-1. Delayed turnover in the placebo group The most significant change before and after ingestion of the placebo beverage was the improvement in transepidermal water transpiration (TEWL). TEWL is an index that evaluates the barrier function of the skin by measuring the amount of water that evaporates from the body. A high TEWL represents a state in which the barrier is broken and a lot of moisture escapes, which is generally not preferable. Therefore, when this value decreases, it can be evaluated that the barrier function is improved. However, if the skin condition is judged only by this index, it may fall into a big error.
For example, when the turnover stratum corneum storing thicker decreases with age, it may apparently TEWL improves (the value becomes smaller). Such a condition is often seen in the elderly. However, in the skin of elderly people, the amount of water in the stratum corneum is low and often dry.
In addition, it may not be said that a high TEWL is necessarily a bad state. Baby's skin has high TEWL. However, the baby's skin has a high moisture content in the stratum corneum and is very moisturized. As described above, it is impossible to determine the skin state by TEWL alone. It is important to make comprehensive judgments including other parameters such as stratum corneum moisture content (skin measurement / evaluation on site level-trouble cases / measures-Science & Technology Co., Ltd. (2007), Chapter 24) .
Considering such points, when examining the results of this example, the TEWL measurement value of the placebo intake group is from 20.5 ± 6.6 g / m ² · h before intake, to 18.7 ± 5.9 g / m ² after intake. It changed to ² · h, and a statistically significant difference was observed. However, in the placebo group, stratum corneum water content did not improve significantly before and after ingestion, and texture showed a tendency to deteriorate (p <0.1). If this result is comprehensively judged, it is estimated that the placebo intake group may have been affected by the seasonal change, that is, the turnover delay may have occurred with the seasonal change.

2-2. Deterioration of pigmentation in the placebo-ingested group After the improvement of TEWL, the remarkable change observed in the placebo-ingested group is the deterioration of pigmentation (image analysis). Spots are produced by the production of melanin by melanocytes activated by UV light. From the results of the image analysis, it was found that the large and dark spots (large II, III) became larger and the number increased in the placebo intake group. Furthermore, inflammatory cytokine (IL-8), which is known to increase production in keratinocytes by ultraviolet rays, was significantly increased in the stratum corneum of the placebo group. This can be said to be data supporting the result of the influence of the increase in the amount of ultraviolet rays from February to April when this example was implemented.
Furthermore, the delay of turnover in the placebo intake group may have caused a delay in melanin discharge (suppression). Normally, melanin produced by melanocytes is recognized as a stain because it accumulates in keratinocytes. Because the turnover was delayed in the placebo group, it is possible that melanin proliferated and blemishes grew before keratinocytes detached.

3. Profec skin quality improvement effect In skin analysis (instrument measurement / image analysis), stratum corneum water content and texture score improved significantly in the Profec intake group compared to the placebo intake group. In the questionnaire survey showing the actual feeling of the subjects, the conspicuous pores, texture, wrinkles and transparency were improved. These four items are the most common skin troubles for women, and although they are expressed differently, all of them are items that can be realized by maintaining normal turnover of the stratum corneum and improving the water content of the stratum corneum. As described above, turnover delay may have occurred due to seasonal variations during the period in which the present embodiment was implemented. In this example, the index indicating the turnover is not measured, but in addition to the improvement of the stratum corneum moisture content and the texture score, the questionnaire index (conspicuous pores, closely related to those measured values) The improvement effect is also observed in the texture, wrinkles, and transparency, suggesting that Profec may have a normalizing effect of turnover.
The relationship between each questionnaire item and stratum corneum water content, texture score, and turnover is described below.

3-1. Conspicuous pores Conspicuous pores means that the periphery of the pore outlet is recessed in a mortar shape and is recognized as a pore in the shadow. It is known that the stratum corneum in the part where the pores are depressed is in an abnormal turnover state (failed keratinization state) (Fragrance J. 35 (1): p19, 2007). Such parakeratosis is induced by unsaturated fatty acids in the sebum. In this example, there was no result of measuring the turnover of the stratum corneum, and there was no change in the amount of sebum. However, in the Profec ingestion group, the skin pH changed from pH 6.0 before ingestion to pH 5.5 after ingestion, suggesting that the composition of sebum has changed. Profec intake may improve the sebum composition and improve the turnover of the stratum corneum in the pores, which may result in the pores becoming inconspicuous.

3-2. Texture Texture is an index that represents the surface morphology of the skin. Observing the skin, which runs fine grooves reticulated, portions surrounded by the groove has a triangular, rhombic or square. This groove is called a skin groove, and the part surrounded by the skin groove is called a hide hill. In general, when it is said that the skin is fine, the crevice is narrow and shallow, and the cuticle has a regular shape. Conversely, the wider and deeper the crevice is, the more conspicuous the hill is. Furthermore, if the skin is uneven, the skin surface feels rough and the skin becomes rough. When normal turnover is maintained and the keratinocytes normally undergo terminal differentiation (keratinization), the shape of the keratinocytes becomes uniform and a healthy stratum corneum with high water retention is formed. This is said to be in order.
In the present embodiment, the stratum corneum moisture content is significantly increased in addition to the improvement of the index indicating texture. It can be said that the improvement result of the texture score (image analysis) in the Profec intake group observed in this study is an improvement effect accompanied by actual feeling.

3-3. Wrinkles If the skin is dry, the stratum corneum becomes thick, and the exfoliation of the stratum corneum does not proceed normally, shallow wrinkles will be caused. It is said that if the turnover of the stratum corneum is controlled and moisturized sufficiently, shallow and fine wrinkles will disappear (Anti-aging series No.2 forefront of anti-aging skin, NTS Corporation (2006 )). Therefore, wrinkles may have been improved as the stratum corneum moisture content was improved.

3-4. Transparency A highly transparent skin is deep and finely textured, and has a high amount of stratum corneum moisture, low melanin and hemoglobin (Fragrance J. 35 (2): p18, 2007). In this example, a significant improvement effect of stratum corneum water content and texture score was observed in the Profec intake group. This is thought to have led to an improvement in transparency.

4. Pigmentation (stains)
As mentioned above, it is thought that the spot increased and expanded in the placebo intake group as a result of an increase in the amount of ultraviolet rays due to seasonal changes. On the other hand, no positive improvement effect of spots was observed in the Profec intake group. However, in the Profec intake group, also it was observed increase and expansion of significant stains were observed in the placebo intake group. Also in the stain item of the questionnaire, a significant stain improvement effect by Profec intake is shown. As a mechanism of the effect of inhibiting the growth of spots by Profec, it is conceivable to suppress the inflammation of skin, to suppress tyrosinase activity, and to improve turnover (delay suppression).
According to the results of measurement of inflammatory cytokines in the stratum corneum measured in this example, IL-8 was significantly increased in the placebo-ingested group, but IL-8 production was not changed in the Profec-ingested group. This result agrees well with the previous image analysis result. Profec is thought to suppress the growth (increase / expansion) of spots by suppressing IL-8 production. Such inflammation-suppressing effects of Profec have been confirmed in animal experiments. Moreover, the inhibitory effect of tyrosinase activity has been confirmed in vitro by the action of DHNA contained in Profec. It is also possible that DHNA contained in Profec taken orally moved into the blood and directly acted on melanocytes. Furthermore, due to the suppression of turnover delay in the Profec intake group, keratinocytes exfoliated before melanin proliferated, and the growth of spots was also considered to be a cause.

Pigmentation worsened in the placebo group, whereas pigmentation did not change in the Profec-containing acidic drink group. However, in the group containing Profec-containing yogurt beverages, the number and area of pigmentation were significantly improved before and after ingestion. This suggests that yogurt components including lactic acid bacteria may have contributed to the improvement of pigmentation. It is known that the activation of macrophages of immune cells contributes to the improvement of pigmentation such as spots. It is suggested that the significant improvement in the number and area of pigmentation may be a result of activation of immune cells including macrophages in the components contained in yogurt including lactic acid bacteria.
In this example, 4 weeks, which is one turnover of human skin, was set as the intake period. The evaluation of skin with food usually sets an intake period of 8 to 12 weeks, so the intake period may be short to fully evaluate the effect. Nevertheless, since the effects described above were observed, Profec's improvement effect on the skin is considered to be very high.

[Example 4] Evaluation of melanin production inhibitory effect of DHNA
Purpose In general, melanin is a source of stains, so it is sparse from the viewpoint of beautiful skin. Therefore, many cosmetics containing a whitening material having an ability to inhibit melanin synthesis have been developed. Hydroquinone with two -OH groups on the benzene ring is currently known as the most powerful whitening agent and is also called "skin bleach". However, for reasons such as would be bleaching white and skin to too strong, it is necessary to a doctor's prescription to use. Meanwhile arbutin hydroquinone glycosides, it is blended in commercial whitening agent because there is no effective as hydroquinone. The melanin production inhibitory effect of DHNA and ACNQ contained in Profec manufactured by Meiji Co., Ltd. was examined from the viewpoint of the tyrosinase activity inhibitory effect and the melanin production inhibitory effect by melanoma cells.

Reagent preparation (Tyrosinase activity inhibition test)
DHNA and ACNQ dissolved in DMSO as a sample, PTU (phenylthiourea) dissolved in DMSO as a positive control, kojic acid and arbutin (Arubutin) dissolved in 0.1 M phosphate buffer (pH 6.8), Each sample was prepared at 2 μM to 200 mM at a concentration before addition (ACNQ only 2 μM to 20 mM) and used for the experiment. Concentration or final concentration in the reaction solution are each 0.1 ~ 10000μM (ACNQ only 0.1 ~ 1000μM), DMSO concentration in the reaction solution is 5%.

Preparation of assay medium (melanin production test)
As a basal medium, 10% FCS-EMEM (containing antibiotics) was used. Media containing samples (DHNA, ACNQ) and positive controls (PTU, Arubutin, Kojic acid), negative controls (PBS, DMSO) have final concentrations of 1 nM-100 μM for DHNA, 1 nM-10 μM for ACNQ, and positive controls It was prepared by diluting with basal medium so that 100 μM and the negative control were 0.1%.

Evaluation of tyrosinase activity inhibitory effect (method)
The measurement method was carried out with a slight modification to the method of Yoshikawa et al. (Yoshikawa M, Biosci. Biotechnol. Biochem., 69 (12): 2368-73, 2005). All reactions were performed in triplicate on a 96-well plate.
First, as a substrate, 50 μL of 2 mM L-DOPA was mixed with 90 μL of 0.1 M Phosphate buffer (pH 6.8) and 10 μL of sample in a well, and preincubated at 37 ° C. for 5 minutes. Next, 50 μL of Tyrosinase (derived from mushroom, Sigma) adjusted to 100 unit / mL with 0.1 M Phosphate buffer (pH 6.8) was added and incubated at 37 ° C. for 15 minutes, and then the absorbance (405 nm) was measured.

(result)
The activity at each concentration when the phosphate buffer was 100 was evaluated. Activity by DMSO (final concentration 5%) of the solvent is decreased 20-30%, but it was found that the concentration-dependent manner activity is inhibited by DHNA. When compared with DMSO, it can be said that there is a remarkable effect when the concentration of DHNA is 10 μM or more. Meanwhile, ACNQ concentration-dependent inhibitory activity was not observed, compared with DMSO, and found that almost no inhibiting tyrosinase activity.
The results of positive controls PTU, kojic acid and arbutin which are known to have tyrosinase inhibitory ability will be described. For PTU, the activity dropped sharply at concentrations of 1 μM and above. Therefore, when the concentration was reassigned between 0.1 and 1 μM and remeasured, concentration-dependent inhibitory activity was observed in this concentration range.
Kojic acid was not significantly different from the negative phosphate buffer in the range of 0.1-100 μM. Compared to DHNA, kojic acid has a higher inhibitory activity at a concentration of 10,000 μM, but DHNA is higher at a concentration of 100 to 1000 μM. On the other hand, arbutin, which is a hydroquinone glycoside, did not show significant inhibitory activity on concentration-dependent tyrosinase activity. From these results, it can be said that DHNA has a stronger inhibitory effect on tyrosinase activity than arbutin.

Evaluation of melanin production inhibitory effect (assay method)
B16 strain was inoculated into a 12-well plate at 1.9 × 10 ⁵ cfu / well and cultured overnight. On the next day, the medium (10% FCS-EMEM) containing the sample was changed and cultured for 3 days. On the completion day of the culture, the cells were washed with PBS, and the cells were lysed by adding 500 μL / well of 1N NaOH. The lysed cell solution was transferred to a 96-well plate at 100 μL / well x 3 wells per sample, and the amount of melanin was measured by absorbance (405 nm) (Curto EV, Biochem. Pharmacol., 57: 663-672, 1999, Dooley TP, Skin Pharmacol., 7: 188-200, 1994, Virador VM, Anal. Biochem., 270: 207-219, 1999).

(result)
The assay results are shown in FIG. Since the final concentration of the solvent (DMSO) dissolving DHNA, ACNQ, etc. was adjusted to 0.1%, inhibition of melanin production by DMSO was not observed. Both DHNA and ACNQ produced only about 60% of melanin in DMSO (solvent target) at 1 nM, suggesting that melanin production is more effective than 100 μM arbutin, kojic acid and PTU as positive controls. It was done.
It was suspected that the melanin production-suppressing effect was due to cytotoxicity by DHNA or ACNQ. Therefore, cell proliferation ability was measured simultaneously. However, in each sample, growth activity equal to or higher than that of only the basal medium (Medium) was observed (data not shown). Therefore, it was confirmed that the melanin production inhibitory effect of DHNA and ACNQ is not due to the cytotoxic effect.
(Discussion)
DHNA and ACNQ were found to suppress melanin production. However, the effect on tyrosinase activity was found to be different between the two. That is, DHNA suppresses melanin production by an action mechanism mediated by tyrosinase activity inhibition, whereas ACNQ suppresses melanin production by an action mechanism other than tyrosinase activity inhibition. It became clear by.

[Example 5] Preparation of tablets of propionic acid bacteria culture (1)
721 parts by weight of fish scale collagen peptide, 8.1 parts by weight of fermented glucosamine, 4.1 parts by weight of arginine, 32.9 parts by weight of reduced maltose, and 200 parts by weight of powdered propionic acid bacteria culture (DHNA: 81 μg / g), Prepare a pullulan aqueous solution in which 3.0 parts by weight of pullulan is dissolved in 100 parts by weight of hot water after mixing and heating in a fluidized bed granulator (Freund Sangyo Co., Ltd.) and spray the pullulan aqueous solution in the granulator. And granulated. After the spraying and granulation was completed, the product was dried until the water content became 3%, cooled, and passed through a 14 mesh sieve to remove large granules. Then, 20 parts by weight of glycerin fatty acid ester having an HLB value of 2.1 and 10.9 parts by weight of sodium L-ascorbate were added thereto and mixed uniformly. The obtained mixed powder is compression-molded with a tableting machine (manufactured by Hata Kogyo Co., Ltd.) to a hardness of 3 kgf, and a circular tablet (tablet) with a weight of 0.25 g and a diameter of 8 mm Manufactured. As a result of the follow-up of the produced tablets at 23 ° C. for 6 months, 98% (probability) or more of DHNA remained, so it was confirmed that the active ingredients were stably present even in the tablets. Moreover, the compounding table in the state where the water | moisture content of a tablet is zero is as follows.
Recipe 1
--------------------------------------------------
Ingredient name Mixing rate (%)
--------------------------------------------------
Fish scale collagen peptide 72.1
Fermented glucosamine 0.8
Arginine 0.4
Propionic acid culture powder 20.0
Reduced maltose 3.3
Pullulan 0.3
Sodium L-ascorbate 1.1
Glycerin fatty acid ester 2.0
--------------------------------------------------
Total 100.0

[Example 6] Production of tablets of propionic acid bacteria culture (2)
706 parts by weight of fish scale collagen peptide, 8.1 parts by weight of fermentation glucosamine, 4.1 parts by weight of arginine, 21.9 parts by weight of reduced maltose, and 200 parts by weight of powdered propionic acid bacteria culture (DHNA: 81 μg / g), A pullulan solution prepared by dissolving 3.0 parts by weight of pullulan, 10.9 parts by weight of orange fruit juice and 5.0 parts by weight of carotene pigment in 100 parts by weight of hot water is prepared in a fluidized bed granulator (Freund Sangyo Co., Ltd.). The pullulan solution was sprayed in a granulator and granulated. After the spraying and granulation was completed, the product was dried until the water content became 3%, cooled, and passed through a 14 mesh sieve to remove large granules. Then, 20 parts by weight of glycerin fatty acid ester having an HLB value of 2.1, 10.9 parts by weight of sodium L-ascorbate and 10 parts by weight of powdered orange flavor were added and mixed uniformly. The obtained mixed powder is compression-molded with a tableting machine (manufactured by Hata Kogyo Co., Ltd.) to a hardness of 10 kgf, and a circular tablet (tablet) with a weight of 1.0 g and a diameter of 15 mm Manufactured. As a result of the follow-up of the manufactured tablets at 23 ° C for 6 months, 98% (probability) or more of DHNA in the propionic acid bacteria culture remains, confirming that the active ingredients are stable even in tablets. did. Moreover, the compounding table in the state where the water | moisture content of a tablet is zero is as follows.
Formulation Table 2
--------------------------------------------------
Ingredient name Mixing rate (%)
--------------------------------------------------
Fish scale collagen peptide 70.6
Fermented glucosamine 0.8
Arginine 0.4
Propionic acid culture powder 20.0
Reduced maltose 2.2
Orange juice 1.1
Carotene pigment 0.5
Powdered orange flavor 1.0
Pullulan 0.3
Sodium L-ascorbate 1.1
Glycerin fatty acid ester 2.0
--------------------------------------------------
Total 100.0

[Example 7] Production of tablets of propionic acid bacteria culture (3)
721 parts by weight of fish scale collagen peptide, 8.1 parts by weight of fermented glucosamine, 4.1 parts by weight of arginine, 51.0 parts by weight of reduced maltose, 200 parts by weight of powdered propionic acid bacteria culture (DHNA: 81 μg / g), silicon dioxide 16.0 parts by weight were added and mixed uniformly with a V-shaped mixer. The resulting mixed powder is compression-molded with a tableting machine (manufactured by Hata Kogyo Co., Ltd.) to a hardness of 8.0 kgf, and a circular tablet (tablet with a weight of 0.25 g and a diameter of 8 mm) (tablet ) Was manufactured. As a result of the follow-up of the manufactured tablets at 23 ° C for 6 months, 98% (probability) or more of DHNA in the propionic acid bacteria culture remains, confirming that the active ingredients are stable even in tablets. did. Moreover, the compounding table in the state where the water | moisture content of a tablet is zero is as follows.
Recipe 3
--------------------------------------------------
Ingredient name Mixing rate (%)
--------------------------------------------------
Fish scale collagen peptide 72.1
Fermented glucosamine 0.8
Arginine 0.4
Propionic acid culture powder 20.0
Reduced maltose 5.1
Silicon dioxide 1.6
--------------------------------------------------
Total 100.0

The composition containing the culture of propionic acid bacteria provided based on the present invention can be used as an agent for improving skin condition, particularly as an inhibitor of pigment formation, by oral administration. The compositions of the present invention, formulated into foods such as nutrients and yogurt, can also be utilized as a composition for oral ingestion it can be expected the improvement of the skin condition. The component which comprises the composition of this invention is comprised with the component demonstrated that it was excellent in safety | security and taste from a long food experience, and it can be ingested over a long period of time. The composition of the present invention can additionally contain a milk fermentation component. The composition of the present invention can be expected to have an intestinal regulating effect in addition to the skin condition improving effect by ingesting the composition.

Claims

A composition for improving skin condition, comprising at least one component selected from the group consisting of (a) to (c) below:
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
The composition according to claim 1, wherein the propionic acid bacterium is Propionibacterium freudenreichii.
The composition according to claim 1 or 2, further comprising a milk fermentation component.
The composition according to claim 3, wherein the milk fermentation component is milk obtained by fermenting milk with one or both of lactic acid bacteria belonging to the genus Lactobacillus and lactic acid bacteria belonging to the genus Streptococcus, or a mixture thereof.
The composition according to any one of claims 1 to 4, wherein the culture of propionic acid bacteria is sterilized.
Analogs of DHNA or ACNQ include 1,4-naphthoquinone, 2-methyl-1,4-naphthoquinone, 4-amino-2-methyl-1-naphthol, and 2-amino-3-chloro-1,4-naphthoquinone The composition of claim 1, wherein the composition is selected from the group consisting of:
The improvement in skin condition is at least one improvement action selected from the group consisting of an improvement in texture density, an increase in stratum corneum water content, and a decrease in pigmentation. Composition.
The composition according to any one of claims 1 to 7, which is a formula such as infant formula, infant formula, food such as lactating milk, health functional food, food for patients, dairy products, or fermented milk.
Use of the composition according to any one of claims 1 to 8 for producing a skin condition improving composition.
A pigmentation inhibitor in the skin, comprising at least one component selected from the group consisting of:
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
A method for improving skin condition comprising the step of orally administering to an animal at least one component selected from the group consisting of (a) to (c) below:
(A) a culture of propionic acid bacteria,
(B) DHNA or an analog thereof, and (c) ACNQ or an analog thereof.
The composition according to any one of claims 1 to 8, which is formed into a tablet.
The pigment formation inhibitor of Claim 10 shape | molded in the tablet (tablet).